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1. INTRODUCTION 
 
1.1 Atopic diseases in childhood 
 
The term atopy describes an inherited predisposition towards the development of a certain 
allergic hypersensitivity. Atopic subjects suffer from diseases like atopic eczema (atopic 
dermatitis), allergic asthma and allergic rhinitis (hay fever) (Biedermann and Rocken, 1999). 
The underlying pathophysiology is mediated by different immunoregulatory pathways and 
interaction of the innate and adaptive immune system. These two major parts of immune 
defence have to be efficiently regulated by itself and closely connected in their regulation in 
order to keep a healthy immune balance. Besides T cell mediated immune responses, the 
humoral and the mucosal immune system play a prominent role in the adaptive immune 
defence (Raedler and Schaub 2013, in press). A dysregulation of this balance is present in 
atopic individuals, with less robust cell-mediated innate immune responses to most antigens, 
but increased humoral (IgE-mediated) responses to allergens (Umetsu et al. 2002). 
Thymus-derived T cells play a critical role in cell-mediated immunity and in atopic diseases. T 
cells can differentiate into several T helper cell (Th) subsets, including Th1, Th2, Th9, Th17, 
Th22 or follicular helper cells (Tfh), which all facilitate different types of immune responses 
(Figure 1; overview innate/adaptive immune system).  
Allergic sensitization describes the reaction of the immune system to allergen exposure, 
associated with induction of Th2 cell differentiation and secretion of the respective Th2 
cytokines, such as IL-4. IL-4 activates B cells which in turn produce allergen-specific 
immunoglobulin E (IgE) antibodies. Contact of the antibodies to other immune cells, 
particularly to mast cells and basophils, results in a coating of these cells with specific IgE. 
Further contact to the respective allergen then leads to an early/immediate allergic response, 
associated with release of preformed mediators such as histamine and tryptase as well as de 
novo generated leukotrienes and prostaglandin D2. A second, late phase arises after 4 to 8 
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hours upon allergen exposure as consequence of the mediators and cytokines released during 
the early phase. This phase is characterized by the recruitment of inflammatory cells and 
infiltration into the lamina propria of the mucosa (Dykewicz and Hamilos, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of the initiation and interaction of the innate and adaptive immune 
system. CTL, cytotoxic T lymphocyte; DC, dendritic cell; G-CSF, Granulocyte-colony stimulating factor; IFN-
, Interferon-gamma; Ig, Immunoglobulin; IL, Interleukin; LL-37, cathelicidin, antimicrobial peptide; MHC II, 
major histocompatibility complex; MOs, microorganisms; NK cell, natural killer cell; NOD, nucleotide-binding 
oligomerization domain containing; PMN, polymorphonuclear neutrophil; TH, T helper cell; TNF-, tumor 
necrosis factor-alpha; TCR, T cell receptor; TLR, Toll-like receptor (Raedler and Schaub 2013, in press).  
 
 
 
Atopic dermatitis (AD) is a chronic inflammatory dermatosis, characterized by pruritus, xerosis 
and shows a close association with IgE-mediated sensitization to foods and aeroallergens. It 
affects small children and infants essentially. Clinically, AD can be divided in two distinct 
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phases, an early acute phase, which is a Th2-mediated process accompanied by high expression 
levels of the Th2 cytokines IL-4, IL-5 and IL-13 and a second chronic phase, in which IL-12 
production by various cell types results in a switch from a Th2 to a Th1-type cytokine milieu, 
associated with an increase in IFN-expression.  
More than half of the children suffering from AD also develop other allergic diseases as 
allergic rhinitis or asthma (paragraph 1.2); this process of sequential manifestations of allergic 
diseases is referred to as “atopic march” (Sabin et al. 2012; Rybojad M., 2012). 
Allergic rhinitis is an allergic inflammation of the nasal airways which causes nasal itching, 
congestion, sneezing and clear rhinorrhea as a response to inhaled allergens by an already 
sensitized individual (Uzzaman and Story, 2012).  Of note, the prevalence of allergic diseases 
and asthma has been increasing dramatically for the last 50 years (Devereux G., 2006). 
 
1.2 Asthma in childhood 
 
Asthma is a complex and heterogeneous disease with respect to its immunopathology as well 
as clinical phenotypes and response to therapies (Holgate S.T., 2008). Asthma is characterized 
by airflow obstruction, bronchial hyperresponsiveness, airway inflammation, increased mucus 
secretion and smooth muscle hypertrophy. It comprises wheezy breathlessness as a 
consequence of airway narrowing, which is partially or totally reversible (Kay A.B., 2001). 
Asthma is a multicellular process involving various different cell types including eosinophils, 
neutrophils, lymphocytes and mast cells. Asthma is not caused by a single gene or 
environmental factor but depends on an interplay between the aforementioned factors, entitled 
as gene-environment interactions (Busse and Lemanske, 2001; Holgate S.T., 2008). 
Asthma in childhood is currently divided in two main phenotypes, the allergic and the non-
allergic asthma (Humbert et al. 1999). Allergic  asthma is caused by inhaltion of environmental 
allergens by an atopic individual, which in turn triggers an early phase response. This early 
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phase is associated with release of inflammatory mediators such as leukotrienes, 
prostaglandins, cytokines and histamines which provoke edema and bronchoconstriction. The 
subsequent late phase is characterized by an activation of eosinophils and infiltration of Th2 
cells into the bronchial mucosa, which in turn increases the production of Th2 and pro-
inflammatory cytokines (Kiley et al. 2007). 
Asthma of non-allergic origin is caused by triggers not related to allergy such as viral 
infections, cold air or exercise (Romanet-Manent et al. 2002). It can be distinguished clinically 
from allergic asthma based on a negative skin prick test to common allergens (Humbert et al. 
1999; Romanet-Manent et al. 2002).  Childhood asthma is currently classified into allergic and 
non-allergic asthma based on clinical criteria and specific sensitization, whereas the detailed 
underlying immunological mechanisms contributing to the pathophysiology of these distinct 
clinical phenotypes are still unknown. 
Besides the allergic and non-allergic asthma classification, further approaches are currently 
discussed (Just et al. 2012), e.g. based on the frequency of symptoms and the age-at-onset to 
segment asthmatic children in early or late-onset asthmatics with transient or persistent 
symptoms (Bisgaard et al. 2001, Papadopoulos et al. 2012). Moreover, multiple-trigger wheeze 
was described for children who respond with wheezing to further triggers, like crying, laughter 
or tobacco. Multitrigger wheeze displays overlapping features with AA and NA, but 
presumably rather reflects a chronic allergic airway disease corresponding to AA (Potter P.C., 
2010; Frey and von Mutius, 2009). 
 
1.3 T cell subsets and function 
 
Besides other immune cells, T cells are thought to be one of the key regulatory cells for the 
development of atopic diseases in childhood (Jutel and Akdis, 2011). Generally, T helper cells 
(Th cells) represent a group of leukocytes which have the expression of the surface marker 
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CD4 in common and play an important role in several processes of adaptive immunity. 
Following T cell development, thymus-derived matured naïve T cells can get activated and 
differentiate into several subsets of T helper cells (Figure 2). During this activation, an antigen-
presenting cell (APC) presents foreign endocytosed and processed material via MHC II to the 
CD4
+
 T cells, which in turn express specific T cell receptors (TCRs) against the peptide/MHC 
II complex. The second activation signal is among others mediated by the co-stimulatory 
molecules CD80 and CD86, which activate the CD28 receptor. Following this 2-signal 
activation, naïve Th cells can differentiate into specific Th subsets.  
The first described T cell subsets were Th1 and Th2 cells (Mosmann et al. 1986). Th1 cells are 
involved in cell-mediated immunity and phagocyte-dependent inflammation, required for 
clearing intracellular pathogens. Th1 cells are the main producers of the cytokines IFN- and 
IL-2. Th2 cells primarily produce the cytokines IL-4, IL-5, IL-10 and IL-13 and besides evoke 
a strong antibody response and eosinophil accumulation. They play a major role in helminth 
and parasitic infections (Romagnani S., 2000). Both cell types (Th1, Th2) express 
characteristic transcription factors, T-bet and Hlx in Th1 and GATA-3 and STAT-6 in Th2 cells 
and their related cytokines act antagonistically (Korn et al. 2009). This Th1/Th2 paradigm of T 
helper cell differentiation, which emerged in the late 1980s, has been expanded following the 
discovery of further T helper cell subsets including Th9, Th17 and Th22 cells, regulatory T 
cells and follicular helper cells (Mosmann et al. 1986).  
Th9 cells are related to Th2 cells as both lineages require IL-4 and the transcription factors 
STAT6 and GATA-3. Chang et al. could show that PU.1 promotes expression of IL-9 and pro-
allergic chemokines and therefore suggest PU.1 as important factor for induction of Th9 
lineage cells (Chang et al. 2010).  
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Figure 2.  T cell activation and effector cell development. 
A foreign protein or antigen (Ag) is taken up by an antigen presenting cell (DC, dendritic cell), processed and 
displayed via MHC II. Upon antigen presentation by dendritic cells, naïve CD4
+
T cells differentiate into unique 
effector T cell subsets; this process is in part determined by the cytokine milieu. The different effector cells are 
classified by the dominant transcription factors in concert with the cytokines they express. Bcl6, B cell lymphoma 
6; GATA-3, GATA-binding protein 3; GM-CSF, granulocyte-macrophage colony-stimulating-factor; INF-, 
interferon-gamma; IL, interleukin; MHC II, major histocompatibility complex II; PU.1 (SPI1), spleen focus 
forming virus (SFFV) proviral integration oncogene; RA, retinoic acid; RORt, RAR-related orphan receptor 
gamma; STAT, signal-transducer and activator of transcription protein; TCR, T cell receptor; Tfh, follicular 
helper cell; TGF-, transforming growth factor beta; Th, T helper cell. 
 
 
Th17 cells are characterized by the cytokines IL-17A, IL-17F and IL-22, which mediate an up-
regulation of pro-inflammatory cytokines, chemokines and metalloproteases. Th17 cells are 
involved in protection against fungi and extracellular bacteria (Akdis et al. 2012) and show 
some kind of plasticity as they can shift to Th1-like cells at inflamed sites (Annunziato et al. 
2012).  
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The cytokine IL-22 is produced by Th17 cells; however it was also identified as key cytokine 
of a distinct CD4
+
 cell subset, the Th22 cells (Duhen et al. 2009, Trifari et al. 2009). Th22 cells 
express high levels of chemokine receptors CCR4, CCR6, CCR10 and the cytokine IL-12 and 
secrete only low amounts of IL-17 (Duhen et al. 2009). Both Th17 and Th22 are involved in 
immune defence to extracellular bacteria and link immune responses to tissue inflammation. 
While IL-17 rather augments inflammation, IL-22 has a more protective function (Akdis et al. 
2012). 
Regulatory T cells (Tregs) represent a heterogeneous group of T cells, responsible for 
maintenance of tolerance to self-antigens, suppression of immunity to pathogens and tumors 
and abrogation of autoimmune diseases. Tregs are characterized by expression of the 
transcription factor (TF) and master regulator FOXP3. Two different origins of FOXP3
+
 cells 
have been described. First, thymus-derived natural regulatory T cells (nTregs), expressing 
CD4, high amounts of the activation marker CD25 and intracellular FOXP3. Second, a group 
of induced Tregs (iTregs), in which expression of FOXP3 is induced in the periphery (Feuerer 
et al. 2009; Sakaguchi et al. 2010). Moreover, two subgroups of induced regulatory T cells 
exist, the TGF- secreting Th3 cells and the IL-10 secreting Tr1 cells, which have been related 
to adaptive regulatory functions without expressing FOXP3 (Curotto de Lafaille and Lafaille, 
2009; Shevach E.M., 2006).  
Most of these different Th cell subsets have the expression or lack of characteristic and unique 
transcription factors and cytokines in common, which are essential for the transcriptional 
programs regulating their differentiation. However, this differentiation state is not completely 
stable and a conversion of Tregs into effector T cells can occur under certain conditions (Beyer 
and Schultze, 2011).  
Quantification of nTregs is problematic due to the fact that activated effector T cells also 
express high amounts of CD25 and can even transiently express FOXP3 (Shevach E.M., 2006). 
1. INTRODUCTION 
 
8 
  
Additional markers can be used for classification as the Treg-associated genes Glucocorticoid-
induced TNF receptor (GITR) and Lymphocyte activation gene-3 (LAG3), though expression is 
not completely Treg-specific (Liu and Raedler et al. 2011). A further possibility to distinguish 
between natural Tregs and activated FOXP3
+
 conventional T cells and iTregs is to investigate 
epigenetic modifications at the FOXP3 locus, particularly at a region called „Treg-specific 
demethylated region“ (TSDR), which was shown to be fully demethylated only in nTregs 
(Baron et al. 2007) and was shown to reliably quantify Tregs already in cord blood (Liu et al. 
2010). 
 
1.4 Role of regulatory T cells and Th17 cells in the development of atopic diseases 
 
1.4.1 Regulatory T cells 
Tregs are supposed to maintain a healthy immune balance and avoid excessive immune 
responses which might cause harmful immune pathology. Consequently, several studies 
suggest an important role for regulatory T cells in various atopic diseases. Tregs were already 
decreased in number as well as suppressive capacity in cord blood from atopic mothers and in 
airways of asthmatic children compared to healthy controls (Schaub et al. 2008; Hartl et al. 
2007). A decrease in Treg functionality was moreover described for allergic asthmatic patients 
compared to healthy controls (Lin et al. 2008; Ling et al. 2004). Although, a potential role of 
Tregs in development of atopic diseases seems to be undisputable, the results on number and 
function in atopic diseases are quite contradictory. While Pumputiene et al. reported no 
differences in Treg numbers between allergic asthmatics and healthy controls (Pumputiene et 
al. 2011), Smyth et al. and Shi et al. published higher numbers of Tregs in the airways of 
asthmatics and in PBMCs of allergic asthmatics during acute exacerbation, respectively 
(Smyth et al. 2010; Shi et al. 2004). Increased numbers of Tregs were also found in PBMCs of 
patients with atopic dermatitis (Ou et al. 2004). Inconsistency in reported Treg numbers can 
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potentially be explained by  different definitions of Treg cells, often solely based on the surface 
markers CD4 and CD25, but not on intracellular FOXP3. The reported cell numbers might 
therefore include Tregs and also activated T cells.  
 
1.4.2 Th17 cells 
Although Th17 cells were reported to play a role in protection against fungi and extracellular 
bacteria, they were also shown to play a key role in several autoimmune disorders and rather 
have pathogenic than protective function in development of autoimmune and allergic diseases 
(Akdis et al. 2012). Th17 cells are involved in the bone destruction phase of autoimmune 
arthritis (Sato et al. 2006), multiple sclerosis (Klotz et al. 2009), in triggering inflammation in 
systemic lupus erythematosus (Wong et al. 2000) as well as in manifestation of  chronic 
intestinal inflammation in inflammatory bowel diseases (Yen et al. 2006). The key Th17 
cytokine IL-17 is involved in neutrophil maturation, migration and function (Hellings et al. 
2003; Cosmi et al. 2011). Since neutrophils were lately associated with important features of 
human asthma, including airway gland hypersecretion, bronchial hyerresponsiveness (BHR) 
and airway wall remodelling, IL-17 was suggested to contribute to the chronic inflammatory 
changes in allergic asthmatics (Molet et al. 2001; Hellings et al. 2003) as well as in the 
pathogenesis of severe, neutrophilic and steroid-insensitive asthma (Alcorn et al. 2010). In 
addition, Zhao et al. reported a relation of Th17 cell numbers with asthma severity (Zhao et al. 
2010). In accordance, IL-17 levels were increased in peripheral blood of patients with atopic 
dermatitis (AD) and as well associated with disease severity in a study by Koga et al. (Koga et 
al. 2008). Ciprandi et al. suggested the use of IL-17 levels in serum as marker for severe 
allergy (Ciprandi et al. 2008).  
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1.5 Genetic and epigenetic changes associated with atopic diseases 
Genetics seem to play a major role in atopic diseases. To reveal whether genetic changes are 
associated with certain diseases, several candidate-specific approaches and genome-wide 
association studies (GWAS) were performed in the last decades. Among others six major 
genomic regions were identified within different GWASs of asthma and asthma-related traits: 
the ORM1-like 3 and gasdermin B (ORMDL3-GSDMB) region, interleukin 33 (IL-33), the IL-1 
receptor-like 1 and IL-18 receptor 1 (IL1RL1-IL18R1) region, the RAD50 homolog and IL-13 
(RAD50-IL13) region, the thymic stromal lymphopoietin and WD repeat domain 36 (TSLP-
WDR36) region and the major histocompatibility complex class II DR/DQ (HLA-DR/DQ) 
region (Moffat et al. 2010; Li et al. 2012). Several studies revealed an association of the 
Chr17q21 locus, including the genes ORMDL3 and GSDMB, with childhood asthma (Moffatt 
et al. 2007; Moffatt et al. 2010; Lluis et al. 2011), however their role in asthma pathogenesis is 
not clear yet. Moreover, single nucleotide polymorphisms (SNPs) within characteristic Th1 and 
Th2 pathway genes were shown to influence development of atopic diseases (Cameron et al. 
2006; Schedel et al. 2008; Suttner et al. 2009; Casaca et al. 2012) and SNPs in various Toll-
like receptor (TLR) genes were shown to affect asthma and atopy risk (Eder et al. 2004; 
Lazarus et al. 2004; Kormann et al. 2009).  
Expression of ten different TLRs was identified in humans so far, which are able to detect 
structural conserved pathogen-associated microbial patterns (PAMPs), including bacterial, viral 
and fungal products as well as damage-associated molecular patterns (DAMPs) that are 
released by cells undergoing necrosis (Holgate S.T., 2012). TLRs, as key molecules in 
recognition of microbial environment, are involved in the induction of expression of co-
stimulatory molecules (Akira and Takeda, 2004). 
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Atopic diseases like asthma were originally described to result from complex gene-
environment interactions. In addition, epigenetic regulation was suggested as potential 
mechanism by which environmental factors could interact with genes involved in disease 
development (Martino and Prescott, 2010). Epigenetics in general describe a change in gene 
expression or the cell phenotype, not mediated by changes in the DNA sequence. Epigenetic 
processes include DNA methylation, histone acetylation, phosphorylation or ubiquitinylation 
and noncoding RNAs (Yang et al. 2012). Epigenetic regulation mechanisms were shown to 
have a major impact on T cell differentiation and regulation of the Th1 and Th2 key cytokines 
IFN- and IL-4, respectively (Wilson et al. 2009; Hughes et al. 2010). Applying a mouse 
model, Brand et al. identified epigenetic modulation as one mechanism by which prenatal, 
microbial exposure contributes to protection against allergy and asthma development in the 
offspring (Brand et al. 2011). 
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1.6 Aim of the study 
 
The prevalence of atopic diseases in childhood increased dramatically over the past decades. 
However, little is known about the underlying mechanisms of immune regulation in infancy 
until the onset of disease. Genetic and environmental factors both contribute to development of 
atopic disease, most likely as interacting factors in a process entitled as gene-environment 
interactions.  
The aim of the present work was to study the impact of SNPs in TLRs and IL-10, as key 
molecules of innate and adaptive immunity, on various aspects of the immune response. Both 
TLR and IL-10 SNPs were associated with inflammatory and atopic diseases in children and 
adults in several studies (Eder et al. 2004; Bossé et al. 2009). We assessed immune regulation 
at the earliest possible time point, in cord blood and the impact of TLR and IL-10 SNPs on the 
manifestation of atopic disease in early childhood. 
 
In the second part, immune regulation later in life, during the manifestation of childhood 
asthma, was investigated. Based on clinical criteria, childhood asthma is currently classified 
into allergic and non-allergic asthma, whereas the underlying immunological mechanisms 
which contribute to the pathophysiology of the two clinical phenotypes are still unknown. Our 
aim was to investigate different T cell populations, with a special focus on Treg and Th17 cells, 
two T cell subsets which are supposed to play a major role in atopic and inflammatory diseases 
(Ling et al. 2004; Molet et al. 2001). In this context, several studies have demonstrated a role 
for epigenetic regulation in T cell differentiation and responses (Lee et al. 2006); however their 
effect on immune regulation in allergic and non-allergic asthmatic children is not clear yet and 
was addressed in this work. 
Different studies have tried to disentangle the asthma phenotypes by Genome-wide association 
studies (GWAS) in which different genotypes were associated with asthma (Moffat et al. 
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2010); however their role in asthma pathogenesis is not clear yet. Aim of this study was to 
identify novel biomarkers and underlying immunological mechanisms of allergic and non-
allergic asthma in childhood.   
The following scientific questions were therefore addressed in this thesis: 
1) To study whether genetic variants in Toll-like receptors or the IL-10 gene already have an 
impact on neonatal immune regulation and development of atopic diseases or wheeze later 
in childhood. 
2) To investigate whether allergic and non-allergic asthmatics and healthy children differ in 
number and function of Tregs and Th17 cells, characteristic T cell subset- and pro-
inflammatory cytokines. 
3) To study whether epigenetic changes have an impact on T cell regulation and development 
of childhood asthma, with a special focus on the IFN- promoter and the Treg-specific 
demethylated region (TSDR). 
4) To investigate if children with allergic and non-allergic asthma can be distinguished 
through microarray-based identification of signalling pathways and differentially expressed 
genes and to identify new biomarkers important in asthma pathogenesis. 
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2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1   Reagents and chemicals 
 
100bp DNA ladder (500μg/ml) New England BioLabs, Ipswich, USA 
ACK Lysis Buffer  Cambrex, East Rutherford, USA 
Anti-human CD4-APC H7 antibody  BD Biosciences, Heidelberg, Germany 
Anti-human CD25-APC antibody  BD Biosciences, Heidelberg, Germany 
Anti-human CD49d-FICT antibody    Beckmann Coulter, Fullerton, USA 
Anti-human FOXP3-PE antibody  eBioscience, San Diego, USA 
Anti-human IL-17-Alexa488 antibody   eBioscience, San Diego, USA 
Anti-human IL-22-efluor660 antibody  eBioscience, San Diego, USA 
Anti-human CD3-PE antibody   BD Biosciences, Heidelberg, Germany 
Anti-human CD4-APC antibody  BD Biosciences, Heidelberg, Germany 
Anti-human CD8-Alexa488 antibody BD Biosciences, Heidelberg, Germany 
Anti-human CD4-FITC antibody Beckmann Coulter, Fullerton, USA 
Anti-human IgG1-APC antibody  BD Biosciences, Heidelberg, Germany 
Anti-human IgG2a-PE antibody eBioscience, San Diego, USA 
Anti-human IgG1-Alexa488 antibody eBioscience, San Diego, USA 
Anti-human IgG1-efluor660 antibody 
Boric acid 
eBioscience, San Diego, USA 
Sigma-Aldrich, Steinheim, Germany 
Bromphenol blue  Roth, Karlsruhe, Germany 
D. pteronyssinus allergen 1 (Derp1)  
EDTA 
Biotechnologies, Charlottesville, USA 
Sigma-Aldrich, Steinheim, Germany 
Ethanol 100%      Merck, Darmstadt, Germany 
Ethidiumbromide (10mg/ml)    Biorad, Hercules, USA 
FACS Clean Solution     BD Biosciences, Heidelberg, Germany 
FACS Flow™ Sheath Fluid    BD Biosciences, Heidelberg, Germany 
FACS Rinse Solution     BD Biosciences, Heidelberg, Germany 
Ficoll-Paque™ PLUS     GE Healthcare, Piscataway, USA 
Fixation/Permeabilization Concentrate  BD Biosciences, Heidelberg, Germany 
Fixation/Permeabilization Diluent BD Biosciences, Heidelberg, Germany 
Foetal Bovine Serum Gold (FBS)   PAA Laboratories GmbH, Pasching, Austria 
Glycerol      Sigma-Aldrich, Steinheim, Germany 
H2O bidest.      H. Kerndl GmbH, Weißenfeld, Germany 
Human serum      Sigma-Aldrich, Steinheim, Germany 
Hydrogen chloride (HCl)    Sigma-Aldrich, Steinheim, Germany 
Ionomycin      Sigma-Aldrich, Steinheim, Germany 
Isolation buffer Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Isopropanol 100%     Merck, Darmstadt, Germany 
LiChrosolv H2O (HPLC)    Merck, Darmstadt, Germany 
Lipid A Sigma-Aldrich, Steinheim, Germany 
Paraformaldehyde  
Penicillin/Streptomycin    
Sigma-Aldrich, Steinheim, Germany 
Gibco, Carlsbad, USA 
Phosphate-Buffered Saline (PBS)    Gibco, Carlsbad, USA 
Phorbol-12-myristate-13-acetate (PMA) Sigma-Aldrich, Steinheim, Germany 
Phytohemagglutinin     Sigma-Aldrich, Steinheim, Germany 
Primers      Life technologies, Invitrogen, Carlsbad, USA 
Rat serum      eBioscience, San Diego, USA 
RPMI 1640 + GlutaMax    Gibco, Carlsbad, USA 
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Trizma Base        Sigma-Aldrich, Steinheim, Germany 
Trypan Blue      Sigma-Aldrich, Steinheim, Germany 
TRIzol Reagent    Invitrogen, Carlsbad, USA 
Tween 20      Merck, Darmstadt, Germany 
Water DEPC (0.1 %)  
 
X-Vivo 15 
Xylene cyanol    
Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Lonza, Cologne, Germany 
Merck, Darmstadt, Germany 
 
 
2.1.2   Solutions and buffers 
 
 
 
 
 
 
 
 
 
 
 
1% PFA 10g paraformaldehyde 
 Ad 900ml ddH2O 
 800μl 1N NaOH 
 30 min at 65°C 
 100ml PBS 10X until pH 7.4 
  
5X TBE buffer 54g trizma base 
 27.5g boric acid 
 20ml 0.5M EDTA (pH 8.0) 
 Ad 1l H2O bidest. 
  
DNA ladder 10μl 100bp DNA ladder 
 80μl 0.5x TBE-Buffer 
 10μl loading dye diluent 
  
Ethidiumbromide [500μg/ml]                  100μl ethidiumbromide 
 1.9 ml H20 
  
FACS buffer 25ml 10X PBS 
 12.5ml FBS (5%) 
 1.25ml Tween 20 (0.5%) 
Ad 250ml LiChrosolv H2O 
  
Loading dye stock solution 0.25g bromphenol blue 
 0.25g xylene cyanol 
 30% glycerol 
 70ml dH2O 
  
Loading dye diluted solution 5ml loading dye stock solution 
 13.5ml glycerol 
 31.5ml dH2O 
  
Medium with 10% human serum  440ml RPMI 1640 + GlutaMAX 
 10ml Penicillin/Streptomycin 
 50ml inactivated human serum 
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2.1.3   Reagent systems (Kits) 
 
CellTrace™ CFSE Cell Proliferation Kit Invitrogen, Carlsbad, USA 
CD3 MicroBeads    Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD4+CD25+ Regulatory T Cell Isolation Kit  Miltenyi Biotec, Bergisch Gladbach, Germany 
FlexiGene DNA Kit      Qiagen, Hilden, Germany 
Human Cytokine Multiplex Assay Kit  Biorad, Hercules, USA 
QIAamp DNA Mini Kit   Qiagen, Hilden, Germany 
QuantiTect Reverse Transcription Kit  Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
SYBR Green PCR Master Mix  Applied Biosystems, Foster City, USA 
 
 
2.1.4   Consumables 
 
96-Well White Shell PCR Plates BD Biosciences, Heidelberg, Germany 
Biosphere® filter tips 10µl M 40mm type D  Sarstedt, Nümbrecht, Germany 
Biosphere® filter tips 100µl     Sarstedt, Nümbrecht, Germany 
Multiwell™ 6 well plates    BD Biosciences, Heidelberg, Germany 
Multiwell™ 12 well plates    BD Biosciences, Heidelberg, Germany 
Multiwell™ 24 well plates    BD Biosciences, Heidelberg, Germany 
Multiwell™ 96 well plates    Greiner bio-one, Frickenhausen, Germany 
SafeGuard Filter tips 100-1000µl   Peqlab, Erlangen, Germany 
  
 
2.1.5   Laboratory equipment 
 
Centrifuge 5810 R / 5417 R / 5415 R   Eppendorf, Hamburg, Germany 
Centrifuge Rotanta 460R / S    Hettich, Tuttlingen, Germany 
Electrophoresis power supply    VWR International, Radnor, USA 
Gel iX Imager      Intas Science Images Instruments, Göttingen, 
Germany 
CFX96 Touch
TM
 Real-time PCR Detection System     Biorad, Hercules, USA 
Incubator Hera Cell 240     Heraeus, Hanau, Germany 
Incubator Heraeus 6000   Heraeus, Hanau, Germany  
LUMINEX 100 IS System    Luminex Corp., Austin, USA 
MACS® MultiStand     Miltenyi Biotec, Bergisch Gladbach, Germany 
Micro Centrifuge II      NeoLab, Heidelberg, Germany 
Microscope Axiovert 40C     Zeiss, Göttingen, Germany 
Neubauer chamber    Karl Hecht KG Assistent, Sondheim, Germany 
Thermocycler Eppendorf Mastercycler   Eppendorf, Hamburg, Germany 
 
 
2.1.6   Software 
       
Bio-plex Manager Software 4.1.1   Biorad, Hercules, USA 
Biorad CFX Manager 2.1    Biorad, Hercules, USA 
CHIP Bioinformatics Tools     http://snpper.chip.org/bio/ 
EndNote X3      ISI ResearchSoft, Berkeley, USA 
Ensembl Genome Browser    http://www.ensembl.org/ 
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Haploview      http://www.broad.mit.edu/mpg/haploview/ 
National Center for Biotechnology 
Information  
R 
http://www.ncbi.nlm.nih.gov/ 
 
http://www.R-project.org/ 
SAS software package version 9.2 
SNPper 
SAS Institute, Cary, USA 
CHIP Bioinformatics Tools 
SPSS version 20     SPSS IBM Inc., Armong, USA 
Vector NTI 10 Advance 11.5 Invitrogen, Carlsbad, USA 
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2.2 Methods 
 
2.2.1   Study population 
 
Two different study populations were investigated in this work. The PAULINA (Paediatric 
Alliance for Unselected Longitudinal Investigation of Neonates for Allergies)/PAULCHEN 
(Prospective Cord Blood Study in Rural Southern Germany) study population, including 200 
neonates with cord blood samples from the Munich outer area (Schaub et al. 2008; Schaub et 
al. 2009) and the CLARA (Clinical Asthma Research Association) childhood asthma 
population, with children aged 4 to 15 years, the latter recruited at the University Children´s 
Hospital, Munich, Germany. 
 
2.2.1.1 PAULINA/PAULCHEN 
Umbilical cord blood (n = 200; 72 samples from atopic mothers, 128 from non-atopic mothers) 
was obtained from healthy neonates born in the Munich metropolitan area, Germany. Subjects 
were recruited from July 2005 to September 2007 during the last trimester of pregnancy. 
Inclusion criteria comprised healthy neonates and mothers with uncomplicated pregnancies. 
Exclusion criteria included preterm deliveries, perinatal infections, maternal use of antibiotics 
in the last trimester and chronic maternal diseases. Detailed information about parental health 
and socioeconomic status was assessed by questionnaires. Maternal atopy was defined as 
doctor’s diagnosis of asthma and/or eczema and/or hay fever. Maternal total and specific IgE 
(RAST) were measured. A positive specific IgE was defined as ≥0.35 IU/mL to one or more 
common allergens from a panel of 20 allergens (Mediwiss Analytic, Moers, Germany; 
dermatophagoides pteronyssinus [D1], dermatophagoides farina [D2], birch pollen [T3], gras 
pollen [GX], egg white [F1], cow´s milk [F2], soybean [F14], hazelnut [F17], latex [K82], 
hazel [T4], cat epithelium [E1], horse epithelium [E3], dog epithelium [E5], Alternaria 
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alternate [M6], peanut [F13], carrot [F31], wheat [F4], mugwort [W6], timothy [G6], plantain 
[W9]). 
The laboratory investigators were blinded to clinical information; samples were analysed based 
on sample availability to perform the laboratory studies. Informed consent was obtained from 
the mothers for their participation in the study, including cord blood collection. Approval was 
obtained from the human ethics committee of the Bavarian Ethical Board, LMU Munich, 
Germany. A total number of 200 children was recruited, the number for the single analyses 
varied due to sample availability or non-participation in the follow up. 
At the age of 3 years, a follow-up of the study population was performed. All data were 
collected in detailed questionnaires answered by the parents. The outcomes included atopic 
dermatitis (AD), food allergy, wheeze and asthma (clinical symptoms and doctor´s diagnosis). 
A positive allergen test was defined by at least one positive RAST to one of the 20 common 
inhaled or food allergens. Wheeze was defined by wheezy symptoms in the last three years. 
Atopy was defined by doctor´s diagnosis of atopy (obstructive bronchitis, asthma, atopic 
eczema or food allergy) or atopic symptoms. AD was defined as doctor´s diagnosis of 
inflammatory, relapsing, non-contagious and pruritic skin disorder and asthma as doctor´s 
diagnosis of chronic inflammatory airway disease characterized by variable and recurring 
symptoms, bronchospasm and reversible airflow obstruction (according to the guidelines of 
ATS/ERS Society Statement, 2005: Beydon et al. 2007; Nielsen and Bisgaard, 2005; Crapo et 
al. 2000). 
 
2.2.1.2 CLARA 
Peripheral blood (n= 230) was sampled from children age 4 to 15 years in the CLARA study, 
Munich, Germany. Enrollment occurred from January 2009 and is still ongoing. Parents were 
approached for consent and completed a detailed questionnaire that assessed infant data. 
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Upon enrollment, all asthmatic children underwent full clinical examination, pulmonary 
function test, chest radiograph and blood count. In addition, total and specific IgE (RAST) 
were measured. A positive specific IgE was defined as one or more positive reactions [≥0.35 
IU/ml] to a panel of 20 common allergens (Mediwiss Analytic, Moers, Germany; for allergen 
details see 2.2.1.1). Reversible airway obstruction was defined as significant difference of the 
forced expiratory volume in one second before and after inhalation of the short-acting 2-
adrenergic receptor agonist salbutamol (FEV1), analogous to ATS/ERS criteria (Beydon et 
al. 2007; Nielsen and Bisgaard, 2005; Crapo et al. 2000).   
Inclusion criteria for asthmatic children comprised at least 3 attacks of obstructive bronchitis 
and/or a doctor´s diagnogis of recurrent episodes of obstructive bronchitis and/or a history of 
asthma medication and a typical lung function showing reversible pulmonary obstruction. 
Children were defined as asthmatics if they met the inclusion criteria for asthmatics and had a 
FEV1 of higher than 10%. Allergic asthmatics (AA) were defined based on the criteria above 
and a positive (>0.35 IU/ml) specific allergic sensitization assessed by RAST test. Non-allergic 
asthmatics (NA) were based on the criteria above and a negative specific allergic sensitization 
assessed by RAST test. The definition for healthy children (HC) was based on having no 
allergies and any chronic diseases. Children with other pulmonary, chronic or autoimmune 
diseases were excluded, similarly children with immunodeficiency and subjects taking steroids, 
antibiotics, probiotics or suffering from an infection within 14 days before blood withdrawal.  
 
2.2.2   Isolation and culture of CBMCs and PBMCs 
 
Cord blood mononuclear cells (CBMCs) cells and peripheral blood mononuclear cells 
(PBMCs) were isolated within maximum 24 hours after blood withdrawal by density-gradient 
centrifugation with Ficoll-Hypaque (Amersham Bioscience, Uppsala, Sweden) after dilution in 
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phosphate buffer saline (PBS, Gibco, Karlsruhe, Germany). Cells were washed with RPMI 
1640. 
CBMCs were diluted to a concentration of 5x10
6
 cells/ml in 10% human serum (Sigma 
Aldrich, Steinheim, Germany). CBMCs were cultured unstimulated or stimulated with lipid A 
(LpA, 0.1μg/ml), peptidoglycan (Ppg, 10μg/ml), phytohemagglutinin (PHA, 5μg/ml), 
Dermatophagoides pteronyssinus (Derp1, 30μg/ml) or a combination of LpA and Derp1 for 3 
days. 
PBMCs were diluted to a concentration of 5x10
6
 cells/ml in X-Vivo (Lonza, Cologne, 
Germany). For RNA isolation and cytokine measurement, 2x10
6
 cells were cultured (24-well 
plate; BD) in X-Vivo for 48 hours either without stimulation or stimulated with platebound 
anti-CD3 (3µg/ml) plus soluble anti-CD28 (1µg/ml), lipid A (LpA, 0.1µg/ml) or peptidoglycan 
(Ppg, 1mg/ml) at 37°C. Cell pellets were used to isolate RNA for quantitative RT-PCR and 
supernatants were used to determine cytokine levels. The peptidoglycan was extracted from 
bacterial culture by the group of Prof. Dr. Otto Holst (Institute of Structural Biochemistry, 
Research Center Borstel, Germany). For flow cytometry staining, 2.5x10
6
 cells were cultured 
(12-well plate, BD) in X-Vivo for 48 hours either without stimulation or stimulated with 
platebound anti-CD3 (3µg/ml) plus soluble anti-CD28 (1µg/ml) and lipid A (LpA, 0.1µg/ml). 
 
2.2.3   Quantitative analysis of regulatory T cells and Th17 cells 
 
PBMCs were analysed using three-colour flow cytometry (FACS canto II, BD, Heidelberg, 
Germany). For surface staining, PBMCs were incubated in aliquots of 2.5x10
5
 cells in FACS 
buffer with saturating concentrations of fluorochrome-labeled antibodies for 20 minutes at 4°C. 
Cells were stained with 1µl CD4 APC-H7, 1µl CD25 APC, 1µl CD49d FICT and 
corresponding isotype controls were used. To distinguish alive and dead cells, cells were 
stained with 7-Aminoactinomycin (7-AAD) for 10 minutes. The samples were washed with 
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1ml RPMI buffer and resuspended in 200µl RBMI buffer. For intracellular staining 5x10
5
 cells 
were incubated with surface antibodies and 7AAD and once washed with RPMI buffer. 
Thereafter cells were resuspended in 250µl freshly prepared fixation/permeabilization solution 
and incubated at 4°C for 30 minutes in the dark. After centrifugation, cells were washed twice 
with 1x CytoPerm/Wash. After blocking with 2% rat serum at 4°C for 15 minutes, intracellular 
antibodies (5µl Foxp3 PE, 5µl IL-17 Alexa488, 1.25µl IL-22 efluor660 and corresponding 
isotype controls) were added and cells incubated at 4°C for 30 minutes in the dark. After two 
further washing steps with 1ml of 1x Perm/Wash, cells were resuspended in 200µl buffer and 
fixed in 200µl 1% PFA. Flow cytometry data were analysed using the FACS DIVA software. 
 
 
2.2.4   Qualitative analysis of regulatory T cells 
 
CD3
-
 cells were isolated with the human CD3 isolation kit (Miltenyi Biotec) and irradiated at 
30 Gy for 10 minutes. CD4
+
CD25
high 
and CD4
+
CD25
-
 cells were isolated in a two-step 
procedure by depleting the non-CD4
+ 
cells, followed by a positive selection of the CD25
high
 
cells (human CD4
+
CD25
high
 isolation kit, Miltenyi Biotec). The purity of all isolated cell types 
was determined by flow cytometry analysis and was above 90%. Cells were stained by mixing 
equal volumes of cell suspension (5x10
6
 cells/ml) with 5µM CFSE in PBS with 10% FBS for 5 
minutes at room temperature in the dark. CFSE treated CD4
+
CD25
-
 cells (2x10
4
 cells/well) 
were incubated with irradiated CD3
-
 cells (4x10
4
 cells/well) in coculture with or without 
CD4
+
CD25
high
 T cells at indicated cell:cell ratios  (2.5x10
3
 to 6x10
4
 cells/well).  
Results were compared before and after stimulation with 0.8 ng/µl PHA. After 72 hours of 
culture, division of CD4
+
CD25
-
 T cells was analysed with FACS Diva Software. The 
suppressive capacity (SC) was calculated with the following formula: 
 
 
SC [%] = (cell division of effector T cells alone) – (cell division of effector T cells with Tregs)  x 100  
(cell division of effector T cells alone)                            
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Cytokine concentrations of IL-1, IL-2, IL-5, IL-9, IL-10, IL-13 and IFN- were measured in 
the Treg suppression assay supernatants of two conditions (irradiated CD3
-
 cells, PHA-
stimulated effector cells without and with Tregs [Teffs:Tregs = 1:0.5]) with the Human 
Cytokine-Multiplex-Assay-Kit (Biorad, Hercules, USA). 
 
2.2.5   Cytokine secretion 
Cytokine concentrations of Interleukin (IL)-2, IL-4, IL-5, IL-10, IL-13, IL-17, Interferon-
gamma (IFN-, Tumor necrosis factor-alpha (TNF- and Granulocyte macrophage colony-
stimulating factor (GM-CSF) were measured in cell supernatants by using the Human 
Cytokine-Multiplex-Assay-Kit according to the manufacturer’s instructions (Bio-Rad, Munich, 
Germany) by LUMINEX technology. The lower detection limits of the assay (pg/ml) were 
0.15 (IL-2), 0.05 (IL-4), 0.12 (IL-5), 0.09 (IL-13), 0.08 (IL-10), 1.04 (IL-17), 0.58 (IFN-), 
0.25 (TNF-) and 1.0 (GM-CSF). 
 
2.2.6   DNA and RNA extraction  
 
DNA from frozen EDTA blood was isolated using the FlexiGene DNA Kit (Qiagen, Hilden, 
Germany). DNA of frozen CD4
+
 cells was isolated using the QIAamp DNA Mini Kit (Qiagen) 
and RNA of PBMCs and CD4
+
 cells was isolated using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer's instructions. 
 
2.2.7   Microarrays 
For microarray experiments, PBMCs from a subgroup of 14 AA, 8 NA and 14 HC 
(“microarray population”) and isolated CD4+ cells from 5 AA and 3 HC were analysed in 
cooperation with the Institute for Medical Microbiology, Immunology and Hygiene, TUM, 
Munich. Total RNA was labeled and hybridized to Affymetrix GeneChip® Human Gene 1.0 
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ST arrays according to the manufacturer’s instructions. The quality of the scanned arrays was 
checked by MvA plots, density plots and RNA degradation plots. All steps were performed 
using R and Bioconductor (Gentleman et al. 2004). RMA, „robust multichip average“ was used 
for background correction, normalization and to control for technical variation between arrays 
within the study (Irizarry et al. 2003). As the samples were labeled and hybridized at different 
timepoints, batch effects had to be included as a covariate into the linear model.  
 
2.2.8   Quantitative RT-PCR 
 
Total RNA (1µg) of CBMCs and PBMCs isolated with TRI reagent and RNeasy mini Kit, 
respectively, was processed with reverse transcriptase (Qiagen, Hilden, Germany). For qRT-
PCR we used 0.24µl cDNA [12ng] of CBMCs or 0.12µl cDNA [6ng] of PBMCs per well. 
Gene-specific PCR products were measured continuously by using the iCycler iQ-multicolor 
Real-Time PCR Detection-System for CBMCs and the CFX96 TouchTM Real-time PCR 
Detection System (Bio-Rad) for PBMCs for 40 cycles. Direct detection of the PCR product 
was monitored by measuring the increase in fluorescence caused by binding of SYBR Green to 
dsDNA. The cyle threshold (CT) describes the number of PCR cycles required for the 
fluorescence signal to exceed the detection threshold. The difference in CT values relative to 
the housekeeping gene 18S was used to calculate the delta CT (∆CT). A higher ∆CT 
corresponds to a lower gene expression. The difference in CT values relative to 18S rRNA was 
used to calculate the fold difference with the formula 2
-∆∆CT
. The relative quantitative results 
were used to determine changes of stimulated/unstimulated samples. All experiments were run 
in duplicates with the same thermal-cycling parameters. Non-template controls and 
dissociation curves were used to detect primer-dimers and nonspecific amplification. PCR 
products were separated on a 3% agarose gel to control for specificity and the expected size of 
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the PCR fragment. mRNA-specific oligonucleotide primers (forward/reverse) were designed 
with Vector NTI Advance 11.5 (Invitrogen, Carlsbad, USA). 
 
2.2.9   Genetics: Polymorphism selection and genotyping 
 
For the selection of polymorphisms in different TLR genes, haplotype tagging SNPs were 
selected for genotyping from all TLR polymorphisms with a minor allele frequency >0.10 
(Haplotype software). Based on previous knowledge, 12 polymorphisms within the human TLR 
genes TLR1, TLR2, TLR4, TLR6 and TLR10 were selected due to their association with asthma 
and their putative functional implications (Liu, Raedler et al. 2011; Eder et al. 2004; Kormann 
et al. 2008).  
Tagging SNPs within the IL-10 gene were selected based on the American (CEU) and 
European (TSI) population samples, genotyped in the HapMap project (Raedler et al. 2012). 
All SNPs located from the proximal promoter (-4000bp) to the 3´UTR and with a minor allele 
frequency >0.1 in both populations were included in the analyses. Polymorphisms with R
2
 ≥ 
0.8 were defined as linkage disequilibrium (LD) block (Figure 6).  
Using Haploview (Version 3.32), four tagging SNPs (rs1800890, rs1800871, rs1878672, 
rs3024498) were selected from all 13 frequent polymorphisms located in the IL-10 region 
(Figure 6). Two further polymorphisms, rs1800893 and rs3024496, which are in close LD with 
rs1878672 and two putative functional variations rs79309463 (deletion) and rs10494879, 
located in the promoter (-7616 and -6424), were genotyped. (Kube et al. 2003; Rieth et al. 
2004; Wilk et al. 2007). In total, seven IL-10 polymorphisms and one deletion were 
investigated. The LD-plot of the eight IL-10 polymorphisms within our study population is 
shown in Figure 7.  
Genotyping was performed by Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (Sequenom Inc., San Diego, CA, USA; Ding and Cantor, 2003) at the Institute of 
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Epidemiology (Helmholtz Centre Munich, Neuherberg, Germany). Polymerase chain reaction 
assays and associated extension reactions were designed with the SpectroDESIGNER software 
(Sequenom Inc.). All amplification and extension reaction conditions have been previously 
described (Kormann et al. 2005). Deviations from Hardy-Weinberg Equilibrium (HWE) were 
assessed for quality control of genotyping procedures. Allele frequencies were compared to the 
HapMap CEPH (Centre d’Etude du Polymorphisme Humain) population.  
 
2.2.10   Epigenetic regulation of IFN- and FOXP3 
2.2.10.1 IFN- promoter and FOXP3 TSDR methylation  
For assessment of the IFN- promoter methylation, CD4+ cells were isolated with the 
autoMACS Pro Seperator, depleting the non-CD4
+
 cells, as recommended by the manufacturer 
(human CD4
+
CD25
high
 isolation kit, Miltenyi Biotec). The purity was determined by flow 
cytometry analysis and was above 90%. Bisulfite conversion of genomic DNA and template 
preparation was performed by the group of Prof. Dr. Harald Renz (Institute for Laboratory 
Medicine and Pathobiochemistry, Philipps University of Marburg, Germany) as described 
elsewhere (Waterland et al. 2006; Tost and Gut, 2007). Pyrosequencing was performed with 
the PyroMark ID System (Biotage AB, Uppsala, Sweden).  
For assessment of the TSDR methylation status, 1.5x10
6
 PBMCs were cultured in 24-well 
plates in X-Vivo without stimulation or following stimulation with platebound anti-CD3 
(3µg/ml) and soluble anti-CD28 (1µg/ml) for 48 hours at 37°C. DNA of PBMCs was isolated 
with QIAamp DNA mini kit (Qiagen). The methylation status of the TSDR region was 
determined with an immune monitoring assay from Epiontis GmbH (Berlin, Germany). 
Bisulfite conversion of genomic DNA, bisulfite sequencing of FOXP3 and GAPDH, and 
quantitative PCR have been previously described (Sehouli et al. 2011). Real-time PCRs were 
performed using the Roche LightCyclerH 480 (Roche, Mannheim, Germany) chemistry or 
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Epitect-MSP (Qiagen) in 20µl, containing 30pmol of methylation- or non-methylation-specific 
forward and reverse primers for TSDR, 5pmol hydrolysis probe, 50ng lambda-DNA (New 
England Biolabs, Frankfurt, Germany) and 60 ng bisulfite-treated genomic DNA template and 
or the respective amount of plasmid standard.  
 
2.2.10.2 IFN- and FOXP3 acetylation  
For IFN- and FOXP3 acetylation analysis, CD4+ cells were isolated by negative selection 
(autoMACS Pro Seperator, Miltenyi Biotec) and CD4
+
 DNA was isolated with QIAamp DNA 
Mini Kit (Qiagen). Chromatin immunoprecipitation (ChIP) was performed by the group of our 
cooperation partner Prof. Dr. Harald Renz in Marburg. Antibodies against acetylated H4 and 
H3 (Upstate Biotechnology, Charlottesville, USA) were used. Purification of the 
immunoprecipated and eluted DNA was performed with QIAquick columns (Qiagen) and 
amplified by means of quantitative PCR. All amplifications were performed in duplicates, 
using 2 µL of DNA per reaction. The duplicate mean values were displayed as the percentage 
of immunoprecipitated DNA compared with total DNA (100% input) (Brand et al. 2011). 
 
2.2.11 Statistical analyses 
Epidemiologic parameters were analysed for all study populations and screened for possible 
confounders. Descriptive statistics were calculated depending on phenotype or genotype. 
Significant differences depending on the phenotype or genotype were analysed by Kruskal-
Wallis-test for ordinal/continuous data or by Chi-square test/Fisher´s exact test for categorical 
data. Data analysis was performed with SAS9.2 (SAS Institute, Cary, NC, USA) and with R 
(Developmental core team, 2005).  
For the SNP analyses, all SNPs were tested for deviation from HWE by using the Chi-square 
test. The LD between the IL-10 SNPs was calculated by using R
2
 and the threshold was set to 
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0.80 to determine tagging SNPs, each representing 1 LD block. The frequency of SNPs and 
genetic analyses were analysed with Chi-square test (two groups) or Mantel-Haenszel test for 
trend (three groups). Not normally distributed data of cytokine concentrations and gene 
expression were analysed with Mann-Whitney rank test (two groups) or Kruskal-Wallis rank 
test (three groups) and results were reported as median (±25-75% interquartile range).  
Additionally, rank transformed gene expression data were analysed by linear regression 
models, including the allele count as linear variable. Data were stratified for maternal atopy. 
For the IL-10 SNPs, diplotype frequencies were estimated by using a combination of 
homozygous carriers of the selected variations. As this was an explorative study and the 
immunologic data were highly correlated, no adjustment for multiple testing was applied. 
Statistical significance was defined as p≤0.05.  
For the microarray analyses, the single gene ranking was performed with the moderated 
Bayesian t-statistics as implemented in LIMMA (Smyth G.K., 2004). Genes which still showed 
a small variability across the samples following normalization were removed with an intensity 
filter (the intensity had to be above 100 in at least 25% of the samples). A further variance 
filter was applied where the interquartile range of log2 intensities was set to at least 0. Multiple 
testing was taken into account by controlling the FDR according to Benjami and Hochbergs 
method (Benjamini and Hochberg, 1995). Acceptance or rejection of each hypothesis test was 
decided upon a series of related t-statistics and classified as up-regulated, down-regulated, or 
not significantly changed (threshold cutoffs: p-value=0.05 and log2 fold-change=0). The 
GlobalAncova analysis was applied to investigate the role of functional gene groups and 
pathways within AA, NA and HC. Differentially expressed genes were analysed using 
Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, Redwood City, USA). 
As PCR data were skewed and partly censored, they were analysed by Tobit regression on rank 
transformed data (Ballenberger et al. 2012). Accordingly, the gene expression values as delta 
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CT (∆CT) were rank transformed and entered in the model as dependent variable, the 
phenotype as independent variable and the stimulation conditions were treated as covariates for 
the gene comparison analysis. The ranks were retransfomed into the original ∆CT unit and 
estimates of each phenotype were presented as medians.  
For analysis of flow cytometry data, ANOVA on log-transformed data was calculated; data 
were normally distributed following log-transformation. The phenotype was used as 
independent variable. Data were presented as boxplots (first/third quartile, median, whiskers 
indicate the maximum and minimum values, dots represent outliers, black line represents the 
geometric mean).  
Treg suppression assays were analysed by a linear mixed model on log-transformed data. 
“Phenotype” and “addition of Tregs” were treated as independent variables. An interaction 
term was entered into the model to assess whether the effect of phenotype on “suppressive 
capacity” depends on “addition of Tregs”.   
Cytokine data were log-transformed in order to meet the assumption of normality. As the data 
contained left censored observations (below detection threshold), a Tobit regression was 
applied with “phenotype” as independent variable and data were presented as boxplots. 
IFN- methylation data were analysed by ANOVA, with “phenotype” as independent variable. 
TSDR acetylation and TSDR demethylation data were analysed by Mann-Whitney test. 
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3. RESULTS 
 
3.1 Immune regulation early in life (Cord blood) 
 
In order to study immune regulation at the earliest possible timepoint, cord blood mononuclear 
cells (CBMCs) were investigated. These cells were used to study the role of genetic variants in 
several candidate genes, which were previously associated with immune-mediated diseases 
such as asthma. For this work, I have focused on single nucleotide polymorphisms in Toll-like 
receptor (TLR) genes, as key modulators of the adaptive and especially innate immune system, 
and in the IL-10 gene, coding for a crucial cytokine with pleiotrophic effects, secreted by 
several cells of the adaptive immune system. 
 
 
3.1.1 Role of TLR SNPs in innate and adaptive immunity in cord blood 
TLRs represent an evolutionarily conserved family of innate pattern recognition receptors, 
capable of activating innate and adaptive immunity (Akira et al. 2001).   
Besides its function in mediating a cellular response to microbial exposure, TLR signalling is 
involved in the generation of Th cell subsets and production of their effector cytokines, 
expression of chemokines and antimicrobial peptides (AMPs) and production of reactive 
oxygen species (Akira et al. 2001, Akira and Takeda, 2004). Moreover, TLRs were proposed 
to directly and indirectly modulate Tregs (Liu and Zhao, 2007), a cell population required to 
keep a healthy immune balance. Thus we studied the impact of TLR polymorphisms on Treg-
associated genes in cord blood. 
 
3.1.1.1  TLR SNP characteristics 
Twelve polymorphisms in TLR1, TLR2, TLR4, TLR6 and TLR10 were genotyped within the 
PAULINA and PAULCHEN study population based on their putative functional implications 
in allergy or asthma development (Eder et al. 2004; Kormann et al. 2008) (Table 1). The 
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genotyping success rate was at least 97% and none of the polymorphisms significantly deviated 
from Hardy-Weinberg equilibrium (data not shown). 
 
Table 1: Biological characteristics of the analysed TLR SNPs 
 
Gene rs  no. 
Position 
rel. 
to ATG* 
Allele Location Δ AA Δ TF 
ESE/ 
ESS 
MAF ISAAC 
Munich 
MAF 
PAULINA/ 
PAULCHEN 
TLR1 rs4833095 743 A/G CDS X  X 0.26 0.29 
TLR1 rs5743595 -2192 T/C Intron  X  0.20 0.21 
TLR2 rs1898830 -15607 A/G Promoter  X  0.33 0.33 
TLR2 rs3804100 1350 T/C CDS   X 0.08 0.07 
TLR2 rs3804099 597 T/C CDS   X 0.45 0.43 
TLR2 rs4696480 -16934 T/A Promoter    0.51 0.54 
TLR4 rs4986790 4435 A/G CDS X X X 0.04
◊
 0.04 
TLR4 rs4986791 4735 C/T CDS X  X 0.06 0.06 
TLR4 rs6478317 -6687 A/G Promoter  X  0.29 0.32 
TLR4 rs10759932 -5724 T/C Promoter  X  0.12 0.14 
TLR6 rs5743789 -2079 T/A Promoter    0.22 0.22 
TLR10 rs4129009 2323 A/G CDS X   0.19 0.21 
*, based on March 2006 human reference (NCBI build 36.1). ISAAC Munich, Munich study population of the 
international study of asthma and allergies in childhood, case-control study.  ◊, not genotyped in Munich, HapMap 
data; rs no., reference SNP ID number; CDS, coding sequence; MAF, minor allele frequency; ∆AA, SNP leads to 
an amino acid change; ∆TF, SNP changes transcription factor binding based on FastSNP analysis; ESE/ESS, SNP 
changes exonic splicing enhancer or exonic splicing silencer based on FastSNP analysis (Liu and Raedler et al. 
2011). 
 
 
 
3.1.1.2  Impact of TLR SNPs on gene expression of Treg-associated genes and Th1, Th2 
 and TNF- cytokine secretion 
 
To study the impact of TLR SNPs on Tregs, we investigated mRNA expression of the Treg-
associated genes FOXP3, GITR and LAG3. Importantly, FOXP3 as Treg transcription factor 
and master regulator is currently representing the most specific Treg marker (Feuerer et al. 
2009). FOXP3 mRNA expression was decreased in homozygous carriers of the TLR1 SNP 
rs4833095 and TLR10 SNP rs4129009 following innate stimulation with LpA or Ppg and in 
homozygous carriers of TLR2 rs3804099 and TLR4 rs10759932 SNP after PHA-stimulation 
(Table 2). Neither the other three TLR4 SNPs nor the TLR6 SNP rs5743789 significantly 
influenced Treg marker gene expression. 
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As maternal atopy in general was identified as important confounder (Schaub et al. 2006; 
Schaub et al. 2008) and differences in allele frequency were detected for the TLR2 SNPs 
rs4696480 and rs1898830 depending on maternal atopy, expression of Treg-associated genes 
was stratified for maternal atopy (Table 2; Figure 3, 4). 
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Table 2: Influence of the 12 assessed SNPs on gene expression of Treg-associated genes 
   and Th1, Th2, and TNF- cytokine secretion 
 
Gene 
rs no. 
SNP 
 
Treg-associated genes 
Th1 Th2 TNF- 
FOXP3 GITR LAG3 
TLR1 
rs4833095 
GG 
all 
↓ LpA* 
Ppg* 
 n.d. 
 
 n.d. 
 
 n.d.  n.d. ↑ Derp1* 
TLR1 
rs5743595 
CC 
all 
 n.d.  n.d.  n.d.  n.d. 
 
 n.d. 
 
 n.d. 
TLR2 
rs1898830 
GG 
CBMCs 
[A] 
↓ U*       
Derp1* 
↓ U* 
Derp1 
↓ U*    
PHA* 
Ppg   
Derp1 
 n.d. ↑ IL-13: 
U*  
PHA  
LpA 
↑ PHA  
LpA* 
Derp1* 
CBMCs 
[NA] 
↑ U*     
LpA* 
↑ U* 
LpA* 
Ppg* 
Derp1 
↑ U*     
LpA*    
Ppg* 
 n.d. 
 
 n.d.  n..d. 
TLR2 
rs4696480 
AA 
 
CBMCs 
[A] 
 
↑ U*     
Derp1* 
↑ U 
Ppg*  
Derp1* 
 
 
↑ U* 
PHA    
Derp1 
 
 n.d. ↑ 
 
IL-5:  
PHA*  
LpA 
↑ PHA 
LpA 
Derp1 
↑ IL-13: 
PHA* 
LpA* 
Derp1* 
CBMCs 
[NA] 
↓ U*    
PHA*  
LpA* 
Ppg 
↓ U* 
PHA 
Ppg*   
Derp1* 
 
↓ U* 
PHA 
LpA 
Ppg*     
Derp1 
 n.d.  n.d.  n.d. 
TLR2 
rs3804100 
CC 
all 
 n.d.  n.d.  Derp1*  n.d. 
 
 n.d. ↑ U* 
TLR2 
rs3804099 
CC 
all 
↓ PHA*  n.d.  n.d.  n.d.  n.d. ↑ U* 
TLR4 
rs4986790 
GG 
all 
 n.d.  n.d.  n.d.  n.d. ↑ IL-13:   
Derp1* 
 n.d. 
TLR4 
rs4986791 
TT 
all 
 n.d.  n.d.  n.d.  n.d. ↑ 
 
IL-13:   
Derp1* 
 n.d. 
TLR4 
rs6478317 
GG 
all 
 n.d.  n.d.  n.d. ↑ IL-12:         
LpA* 
 n.d.  n.d. 
TLR4 
rs10759932 
CC 
all 
↓ PHA*  n.d.  n.d.  n.d.  n.d.  n.d. 
TLR6 
rs5743789 
AA 
all 
 n.d  n.d.  n.d.  n.d.  n.d.  n.d. 
TLR10 
rs4129009 
GG 
all 
↓ LpA 
Ppg 
 n.d.  n.d.  n.d.  n.d.  n.d. 
↑: expression up-regulated; ↓: expression down-regulated; Th1, secretion of IFN-and IL-12; Th2, secretion of 
IL-5 and IL-13; TNF-, secretion of TNF-U, unstimulated; PHA, phytohemagglutinin; LpA, Lipid A; Ppg, 
peptidoglycan; Derp1, Dermatophagoides pteronyssinus. CBMCs [A], CBMCs of atopic mothers; CBMCs [NA], 
CBMCs of mothers without atopy; all, no differentiation according to maternal atopy. rs no., reference SNP ID 
number; n.d., no difference; *, p≤0.05 (Liu and Raedler et al. 2011). 
 
 
The TLR2 SNPs rs4696480 and rs1898830 did not influence Treg marker expression if all 
samples were analysed together. In CMBCs of atopic mothers, homozygous carriers of the 
TLR2 rs4696480 AA genotype showed higher FOXP3, GITR, and LAG3 expression in 
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unstimulated cells (Figure 3 A/C/E, p=0.02/0.08/0.009) and after Derp1-stimulation 
(p=0.01/0.004/0.1) and non-significantly higher expression after PHA-, LpA- and Ppg-
stimulation, compared to carriers of AT and TT. As opposed to this, FOXP3, GITR and LAG3 
expression was lower in the AA genotype compared to AT and TT following all stimulation 
conditions in CBMCs of non-atopic mothers (Figure 3 B/D/F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Association of rs4696480 with FOXP3, GITR and LAG3 expression, 
unstimulated (U) and following stimulation (phytohemagglutinin, lipid A, peptidoglycan, 
dermatophagoides pteronyssinus). Values presented as median ∆ct (interquartile range); higher values 
reflect lower expression (axis vice versa). Kruskal-Wallis test was performed to compare AA (single nucleotide 
polymorphism), AT, and TT. n (maternal atopy) = 15(AA), 16(AT), 8(TT); n (no maternal atopy) = 16(AA), 
33(AT), 18(TT). Gene expression in CBMC of atopic (A, C, E) and nonatopic mothers (B, D, F) for FOXP3, 
GITR, LAG3 (Liu and Raedler et al. 2011). 
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Homozygous carriers of the TLR2 SNP rs1898830 (GG) showed lower FOXP3, GITR and 
LAG3 expression in unstimulated CBMCs in neonates with atopic mothers (Figure 4 A/C/E, 
p≤0.04) and after Derp1-stimulation (p=0.05/0.08/0.06), compared to the AG and AA 
genotype. Opposite effects were observed in unstimulated CBMCs of non-atopic mothers 
(Figure 4 B/D/F, all p≤0.02) or following stimulation with LpA, Ppg (p≤0.04, except for 
FOXP3_Ppg), or Derp1-stimulation for GITR (p=0.09). None of the other TLR SNPs was 
significantly influenced by maternal atopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Influence of the rs1898830 genotype on FOXP3, GITR and LAG3 expression, 
unstimulated (U), and following stimulation (phytohemagglutinin, lipid A, peptidoglycan, 
dermatophagoides pteronyssinus). Values presented as median ∆ct (interquartile range); higher values 
reflect lower expression (axis vice versa). Kruskal-Wallis test was used to compare GG (single nucleotide 
polymorphism), AG, and AA. n (maternal atopy) = 15(AA), 11(AG), 3(GG); n (no maternal atopy) = 11(AA), 
28(AG), 5(GG). Gene expression in CBMCs of atopic (A, C, E) and nonatopic mothers (B, D, F) for FOXP3, 
GITR, LAG3 (Liu and Raedler et al. 2011). 
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Besides effects on Treg marker expression, the TLR2 SNPs rs4696480 and rs1898830 also 
altered Th2 and TNF- secretion. In CBMCs of atopic mothers with TLR2 rs4696480 AA a 
significantly or boarderline higher secretion of IL-5, IL-13 and TNF- was detected, while no 
differences were oberserved if mothers were not atopic (Table 2). No differences were 
oberserved for the Th1 cytokine IFN-. In CBMCs of atopic mothers with TLR2 rs1898830 
GG, IL-13 secretion was lower before and after PHA- and LpA-stimulation and TNF- was 
decreased following LpA-, Ppg- and Derp1-stimulation (Table 2). Again, no effects on 
cytokine secretion were observed depending on the TLR2 rs1898830 genotype in CMBCs of 
mothers without atopy. 
 
 
3.1.1.3  Influence of TLR2 rs4696480 and rs1898830 on TLR2 mRNA expression 
 
We hypothesized that the effect of TLR2 SNPs might be mediated through changes in TLR2 
mRNA expression. There were no differences in TLR2 levels depending on the genotype if 
TLR2 expression was analysed in all cord blood samples independent of maternal atopy (Figure 
5).  
In CBMCs of homozygous carriers of the TLR2 SNP rs4696480 (AA) with atopic mothers, 
TLR2 mRNA was decreased compared to AT and TT carriers following LpA-stimulation 
(Figure 5A, p=0.04). CBMCs of non-atopic mothers with the rs4696480 AA genotype showed 
significantly increased TLR2 expression unstimulated and following PHA-stimulation (Figure 
5C, p=0.05/0.03). In CBMCs of homozygous carriers of the SNP rs1898830, gene expression 
did not differ depending on the genotype. 
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Figure 5. Impact of rs4696480 and rs1898830 on TLR2 mRNA expression.  
Values presented as median ∆CT (interquartile range). Kruskal-Wallis test to compare SNP with heterozygous 
and wildtype genotype. rs4696480: (A) n (maternal atopy) = 10 (AA), 7 (AT), 8 (TT). (C) n (no maternal atopy) = 
9 (AA), 17 (AT), 8 (TT). (E) all. rs1898830: (B) n (maternal atopy) = 10 (AA), 5 (AG), 4 (GG). (D) n (no 
maternal atopy) = 8 (AA), 7 (AG), 3 (GG). (F) all (Liu and Raedler et al. 2011). 
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furthermore investigated genetic variants of IL-10. IL-10 is a pleiotropic cytokine produced by 
a variety of cells of the adaptive immune system, including Th1, Th2, a subset of Th17 cells, 
mast cells, B cells and also Tregs (O'Garra et al. 2007; Taylor et al. 2006). IL-10 inhibits 
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down-regulates pro-inflammatory cytokines including IL-1, IL-6, IL-8, TNF- and GM-CSF 
and was therefore formerly designated as “cytokine synthesis-inhibiting factor” (Fiorentino et 
al. 1991; Grutz G., 2005). IL-10 was described as a candidate gene in the pathophysiologic 
mechanism of autoimmune and inflammatory diseases since it can regulate cellular and 
humoral immunity (Lyon et al. 2004). 
 
3.1.2.1  IL-10 SNP characteristics 
Selection of the tagging SNPs of IL-10 was based on the CEU and TSI population genotyped 
in the HapMap project and is depicted in the LD-plot in Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. LD (R
2
 plots) for 13 frequent IL-10 polymorphisms within the American (CEU) 
and European (TSI) population registered in the HapMap project (minor allele frequency 
>0.1 in both populations). All SNPs were located from the proximal promoter (-4000 bp) to the 3´ 
untranslated region of IL-10. Blocks of tagging SNPs were defined by R
2
 values of greater than 0.80. Shades in 
LD plot (Haploview): white (R
2
=0), gray (0<R
2
<1), and black (R
2
=1). Tagging SNPs are marked with circles. The 
numbers describe the location of the genetic variations in this IL-10 region; in total, the region comprises 35 
genetic variations (Raedler et al. 2012). 
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Besides the four tagging SNPs (rs1800890, rs1800871, rs1878672, rs3024498) from Figure 6, 
we have selected two further SNPs, rs1800893 and rs3024496, which are in close LD with 
rs1878672 and two putative functional variations, rs79309463 (deletion) and rs10494879, 
located in the IL-10 promoter (-7616 and -6424) (Kube et al. 2003; Rieth et al. 2004; Wilk et 
al. 2007). The eight genetic variants of the IL-10 gene were assessed with a genotyping success 
rate of >90% (Table 3). 
 
Table 3: Biological characteristics of the analysed genetic variants of IL-10 
 
SNP/LD-Block SNP Rel. Position* Alleles Location ∆AA ∆TF MF 
Distal promoter 
SNP 1 
rs79309463 -7616 AGG/- promoter 
 
 
 0.21 
Distal promoter 
SNP 2 
rs10494879 -6365 C/G promoter 
 
 
 0.36 
Block 1 rs1800890 -3526 A/T promoter - - 0.32 
Block 2 rs1800871 -795 G/A promoter - + 0.25 
 
Block 3 
 
rs1800893 -1328 C/T promoter - + 0.44 
rs1878672 
(tagging SNP) 
2127 G/C intron - + 0.44 
rs3024496 3976 A/G 3´UTR - + 0.44 
Block 4 rs3024498 4311 T/C 3´UTR - + 0.24 
 
* Relative position, based on SNPper (CHIP bioinformatics Tools); MAF, minor allele frequency within our study 
population; ∆AA, predicted result of amino acid change in protein domain based on FastSNP analyses; ∆TF, 
predicted result of transcription factor binding sites change based on FastSNP analyses. LD blocks are represented 
by one tagging SNP (R
2
 >0.80) (Raedler et al. 2012). 
 
 
The two SNPs rs1800890 and rs1878672 slightly deviated from HWE, but allele frequencies 
were similar compared to the HapMap reference population Centre d’Etude du Polymorphisme 
Humain (CEPH). Figure 7 depicts the LD-plot of the investigated IL-10 polymorphisms within 
our cord blood study population. 
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Figure 7. Linkage disequilibrium 
(R
2
 plot) for the eight investigated 
IL-10 polymorphisms within our 
study population. IL-10_rs number (LD 
block); shades in LD plot (Haploview): 
white (R
2
=0), gray (0<R
2
<1), black (R
2
=1). 
(Raedler et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.2.2  Impact of IL-10 SNPs on cytokine secretion and mRNA expression of Treg-   
.associated genes and IL-10 
 
In homozygous carriers of all investigated IL-10 SNPs except rs1800871 (Block2), the Th2 
cytokine IL-5 was significantly down-regulated (Table 4). No consistent association was 
detected for IL-13 as another Th2 cytokine and mediator of allergic inflammation. The Th1 
cytokine IFN- was, inverse to IL-5, up-regulated in homozygous carriers of the promoter SNP 
rs10494879 and the SNPs from Block 1 and 3. However, it has to be mentioned that highest 
secretion was detected for heterozygous carriers of the SNP. Concentrations of a further Th1 
cytokine, IL-12, were not significantly different in the investigated IL-10 SNPs. There was no 
consistently different pattern for the characteristic Th17 cytokine IL-17. Secretion of the pro-
inflammatory cytokines TNF- and GM-CSF was positively correlated in all stimulation 
conditions and significantly reduced in carriers of both distal promoter SNPs and the SNPs 
from LD block 3 and 4 (Table 4). The pro-inflammatory cytokine IL-6 was not differentially 
regulated depending on the IL-10 genotype. To investigate the impact of the IL-10 genotype on 
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Treg cells, we measured the gene expression of the Treg-associated genes FOXP3, LAG3 and 
GITR, which are highly correlated with each other. 
 
Table 4: Influence of genetic variants of IL-10 on IL-5, IFN-, TNF-, and GM-CSF
      cytokine secretion and gene expression of Treg associated genes 
 
 
↑: secretion/expression up-regulated in homozygous carriers of the minor allele; ↓: secretion/expression down-
regulated in homozygous carriers of the minor allele; U, unstimulated; PHA, phytohemagglutinin; LpA, Lipid A; 
Ppg, peptidoglycan; D, Dermatophagoides pteronyssinus; (fd), gene expression as fold difference; n.d., no 
difference; p-value from Kruskal-Wallis test. *, p≤0.05; all other presented results are p≤0.1.  # highest/lowest 
secretion or gene-expression in carriers with increasing number of the minor allele (SNP-HT-WT); total n=200; 
frequencies of single SNPs were variable depending on MAF (Raedler et al. 2012). 
 
 
LD-Block/ 
SNP 
IL-5 IFN- TNF- GM-CSF 
Treg- 
marker genes 
rs79309463 
↓ U*   n.d. ↓ U* ↓ PHA* ↓      LAG3 U 
LpA* #  LpA # LpA #  LpA # 
D #  Ppg* # D* #  Ppg 
  D*# D+LpA # GITR U* 
  D+LpA #    
rs10494879 
↓ LpA ↑ U* ↓ LpA* # ↓ PHA  n.d.  
D* #  Ppg* # D #   
  D # D+LpA* #   
  D+LpA* #    
Block 1 
rs1800890 
↓ D* # ↑ U ↑ U*  n.d. ↓        GITR U* 
  ↓ Ppg #    
Block 2 
rs1800871 
 n.d.  n.d.  n.d.  n.d. ↓ 
 
FOXP3 LpA* 
    (fd) Ppg* 
    ↑ GITR D 
    LAG3 D* 
Block 3 
rs1878672 
↓ LpA* ↑ D+LpA* ↓ LpA # ↓ D* # ↓ GITR Ppg 
D*  Ppg* #  (fd)  
  D* #    
  D+LpA*    
Block 3 
rs1800893 
↓ LpA* ↑ D+LpA* ↓ LpA #  n.d. ↓ LAG3 D 
Ppg*  Ppg*    
D* ↓ Ppg* D* #    
D+LpA*  D+LpA #    
Block 3 
rs3024496 
↓ LpA* ↑ D+LpA ↓ LpA* # ↓ D  ↓       FOXP3 U 
Ppg      Ppg* #  GITR U* 
D*      D* #  (fd) Ppg* 
D+LpA  D+LpA*  LAG3 U 
Block 4 
rs3024498 
↓ LpA*  n.d. ↓ LpA* # ↓ PHA #  ↓   FOXP3 Ppg* 
D* #  Ppg* LpA* # GITR Ppg 
  D* # D* LAG3 Ppg* 
  D+LpA # D+LpA* #   
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At least one of the three Treg-associated genes was down-regulated in homozygous carriers of 
the SNPs from all four LD blocks (Table 4). An inconsistent regulation was observed for 
carriers of rs1800871, as FOXP3 was significanlty down-regulated while GITR and LAG3 were 
up-regulated. However, FOXP3 currently represents the most specific Treg marker, and 
carriers of the SNPs from block 2, 3 and 4 showed decreased FOXP3 mRNA expression. 
We investigated the influence of the IL-10 genotype on IL-10 at protein and mRNA level. The 
investigated IL-10 SNPs did not show any significant differences in IL-10 levels apart from 
two SNPs. In homozygous carriers of the deletion rs79309463, IL-10 protein but not mRNA 
was decreased without stimulation (p=0.03), however at very low levels. An increase in IL-10 
protein and mRNA was observed for carriers of rs3024496 (block 3) following Derp1-
stimulation (p=0.05 for both, data not shown). 
As we detected an effect of maternal atopy on T-cell immune responses early in life, we 
stratified the data for the atopy status of the mother (Liu and Raedler et al. 2011) and detected 
a minor influence of maternal atopy on the immune response of IL-10 SNP carriers (data not 
shown), with primarily decreased IL-5 and IL-13 levels in CBMCs of non-atopic mothers and 
increased IFN- levels in CBMCs of atopic mothers. FOXP3 expression was increased in 
carriers of the IL-10 SNP rs1878672 following Derp1-stimulation without maternal atopy and 
decreased with maternal atopy. FOXP3 expression was decreased in carriers of the rs1800871 
SNP following LpA-stimulation without maternal atopy, while expression was increased with 
maternal atopy. This diametrical effect of FOXP3 expression was already observed for TLR2 
SNPs, depending on maternal atopy (Liu and Raedler et al. 2011). 
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3.2 Immune regulation during the manifestation of atopic diseases in early childhood  
 
To assess the impact of the SNPs on clinical outcomes, a detailed clinical follow-up was 
performed at the age of 3 years. Data were collected in questionnaires answered by the parents, 
assessing the outcomes atopic dermatitis (AD), wheeze, food allergy and asthma. 
 
3.2.1 Prevalence of atopic diseases and wheeze in carriers of TLR SNPs 
Clinical outcomes regarding atopy in general, AD, asthma, food allergy and wheeze were 
assessed at age 3 years with a follow-up rate of 88%. Several TLR SNPs were associated with 
risk for atopic diseases or wheeze at the age of 3 years. Carriers of the TLR4 SNP rs6478317 
were significantly associated with risk for food allergy (Table 5, p=0.0006) and TLR4 
rs4986790, rs4986791 and TLR6 rs5743789 had an increased risk for AD (Table 5, all p≤0.09). 
 
Table 5: Clinical outcomes of carriers of TLR SNPs at age 3 years 
 
 
 
 
 
 
 
 
 
 
% (n), percentage of children with respective genotype and outcome (number of cases); 0, negative for respective 
outcome; 1, positive for respective outcome; p(MH), p value from Mantel-Haenszel test; x, no SNP genotype in 
study population; atopy, doctor´s diagnosis or symptoms of atopy; wheeze, wheeze in the last 36 month; asthma, 
doctor´s diagnosis of asthma; AD1, doctor´s diagnosis of atopic dermatitis; AD2, atopic dermatitis in the last 36  
months (symptoms); food allergy, doctor´s diagnosis of food allergy (Liu and Raedler et al. 2011). 
TLR SNP Outcome 
WT 
% (n) 
HT 
% (n) 
SNP 
% (n) 
p(MH) 
TLR1 rs5743595 atopy 
0 34 (20) 40 (14) 0 (0) 
0.10 
1 66 (39) 60 (21) 100 (6) 
TLR2 rs1898830 wheeze 
0 54 (20) 64 (30) 85 (11) 
0.07 
1 46 (17) 36 (17) 15 (2) 
TLR2 rs1898830 asthma 
0 76 (19) 92 (24) 100 (9) 
0.14 
1 24 (6) 8 (2) 0 (0) 
TLR2 rs3804100 asthma 
0 85 (74) 100 (12) 0 (0) 
0.05 
1 15 (13) 0 (0) 100 (1) 
TLR4 rs4986790 AD1 
0 86 (77) 62.5 (5) (x) 
0.09 
1 14 (13) 37.5 (3) (x) 
TLR4 rs4986791 AD1 
0 88 (29) 50 (2) (x) 
0.06 
1 12 (4) 50 (2) (x) 
TLR4 rs6478317 food allergy 
0 100 (40) 98 (53) 80 (8) 
0.0006 
1 0 (0) 2 (1) 20 (2) 
TLR6 rs5743789 AD2 
0 71 (77) 71 (39) 44 (4) 
0.09 
1 29 (31) 29 (16) 56 (5) 
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For the two TLR2 SNPs that showed different effects on Tregs depending on the maternal 
atopy status, results on outcomes were also stratified for maternal atopy (Table 6). 
Homozygous carriers of TLR2 SNP rs1898830 were trendwise protected from wheeze and 
atopy if mothers were not atopic (Table 6, p=0.07/0.11). Carriers of the TLR2 SNP rs4696480 
showed a trend for protection against any atopy until 3 years of age if mothers were atopic, 
while the risk for food allergy was increased without maternal atopy (p=0.11/0.10). 
 
 
Table 6: Impact of the TLR2 SNPs rs4696480 and rs1898830 on different clinical 
    outcomes stratified for maternal atopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% (n), percentage of children with respective genotype and outcome (number of cases); atopy, maternal atopy. 0, 
negative for respective outcome; 1, positive for respective outcome; p(MH), p value from Mantel-Haenszel test; 
wheeze, wheeze in the last 36 month; atopy, doctor´s diagnosis or symptoms of atopy; food allergy, skin 
manifestation (Liu and Raedler et al. 2011). 
 
If carriers of both TLR2 SNPs were stratified for maternal atopy, the genotypes with increased 
Treg numbers were associated with a lower prevalence of atopy (rs4696480 SNP and 
rs1898830 SNP; Table 6, both p=0.11) and wheeze (rs1898830 SNP; p=0.07), while the TLR2 
genotypes with decreased Tregs were associated with a higher risk for e.g. food allergy 
(rs4696480 SNP, p=0.10).  
SNP atopy
 
outcome 
WT HT SNP p 
(MH) % (n) % (n) % (n) 
 
rs1898830 
 
0 wheeze 
0 50 (8) 62 (21) 89 (8) 
0.07 
1 50 (8) 38 (13) 11 (1) 
1 wheeze 
0 55 (11) 69 (9) 75 (3) 
0.51 
1 45 (9) 31 (4) 25 (1) 
 
rs1898830 
 
0 atopy 
0 33 (2) 38 (8) 71 (5) 
0.11 
1 67 (4) 62 (13) 29 (2) 
1 atopy 
0 39 (7) 40 (2) 0 (0) 
0.29 
1 61 (11) 60 (3) 100 (2) 
 
rs4696480 
 
0 atopy 
0 48 (10) 30 (9) 29 (2) 
0.54 
1 52 (11) 70 (21) 71 (5) 
1 atopy 
0 0 (0) 23.5 (4) 43 (9) 
0.11 
1 100 (3) 76.5 (13) 57 (12) 
rs4696480 
0 
food 
allergy 
0 97 (29) 93 (51) 84 (21) 
0.10 
l 3 (1) 7 (4) 16 (4) 
1 
food 
allergy 
0 100 (10) 83 (24) 87 (20) 
0.90 
1 0 (0) 17 (5) 13 (3) 
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3.2.2 Prevalence of atopic dermatitis and wheeze in carriers of IL-10 SNPs 
For IL-10 SNPs, the clinical outcomes AD, wheeze and food allergy were assessed with a 
follow-up success rate of 88%. 37.5% of the children showed wheezy symptoms and in 29.5%, 
symptoms of atopy were present within the first 3 years of life. None of the investigated IL-10 
SNPs was associated with food allergy at age 3 years. Having the IL-10 deletion rs79309463 or 
the SNP rs3024498 (block 4) presented as risk factor for wheeze (Table 7, p=0.07/0.02). 
Carriers of the SNP 1800890 were trendwise associated with an increased risk for AD 
(p=0.07). Carriers of both distal promoter SNPs and the SNPs from LD block 1, 3 and 4 were 
associated with an increased risk for AD, wheeze or both at age 3 years (p≤0.04). Moreover, 
the third SNP from block 3 showed a trend for an increased risk in AD, wheeze or both 
(p=0.11, not shown). 
 
Table 7: Clinical outcomes of carriers of IL-10 SNPs at age 3 years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0, negative for respective outcome; 1, positive for respective outcome; AD, any symptoms of AD in the first 3 
years of life; wheeze, any wheezy symptoms in the first 3 years of life; AD/wheeze, symptoms of AD, wheeze, or 
both in the first 3 years of life; HT, heterozygous carrier of the SNP; % (n), percentage of children with respective 
genotype and outcome (number of cases); p (MH), p-value of Mantel-Haenszel test; WT, wild-type (Liu and 
Raedler et al. 2011). 
SNP/ 
LD-Block 
outcome 
WT HT SNP p 
(MH) % (n) % (n) % (n) 
rs79309463 
wheeze 
0 60 (63) 69 (31) 30 (3) 
0.07 
1 40 (42) 31 (14) 70 (7) 
AD/wheeze 
0 45 (47) 55 (24) 10 (1) 
0.04 
1 55 (58) 45 (20) 90 (9) 
rs10494879 AD/wheeze 
0 47 (31) 50 (33) 23 (5) 
0.03 
1 53 (35) 50 (33) 77 (17) 
Block 1 
rs1800890 
AD/wheeze 
0 47 (35) 51 (30) 24 (5) 
0.04 
1 53 (39) 49 (29) 76 (16) 
AD 
0 72  (53) 75 (44) 52 (11) 
0.07 
1 28  (21) 25 (15) 48 (10) 
Block 3 
rs1878672 
AD/wheeze 
0 55 (30) 47 (30) 32 (12) 
0.04 
1 45 (25) 53 (34) 68 (26) 
Block 3 
rs1800893 
AD/wheeze 
0 54 (29) 46 (30) 29 (10) 
0.02 
1 46 (25) 54 (35) 71 (25) 
Block 4 
rs3024498 
wheeze 
0 61 (62) 69 (31) 29 (4) 
0.02 
1 39 (39) 31 (14) 71 (10) 
AD/wheeze 
0 45 (45) 56 (25) 14 (2) 
0.03 
1 55 (55) 44 (20) 86 (12) 
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Although we observed a significant association of 6 SNPs with AD, wheeze or symptoms of 
both on single SNP level (Table 7), no association of the respective haplotypes containing all 6 
minor alleles was detected. 
The most frequent diplotypes of the six genetic IL-10 variants that were associated with an 
outcome at age 3 years are depicted in Table 8. Compared to children having none of the six 
SNPs, who showed a wheeze prevalence of 39.1% and an AD prevalence of 29.4%, 
homozygous carriers of the SNPs rs1878672 (Table 8, SNP4) and rs1800893 (SNP5) showed 
similiar prevalences. Carriers of the aforementioned two SNPs from block 2 (SNP 4, 5) in 
addition to the SNPs rs10494879 (SNP 2) and rs1800890 (block 1, SNP 3) showed an increase 
in AD prevalence from 29.4% (diplotype 0) to 55.6% (diplotype 2).  
 
Table 8: SNP diplotypes of the genetic variants of IL10 associated with outcome at age 3  
    years 
 
 
 
 
AD, Any symptoms of AD in the first 3 years of life; AD/wheeze, symptoms of AD, wheeze, or both in the first 3 
years of life; SNP 1, distal promoter SNP rs79309463 (deletion); SNP 2, distal promoter SNP rs10494879; SNP 3, 
rs1800890 (block 1); SNP 4, rs1878672 (block 3); SNP 5, rs1800893 (block 3); SNP 6, rs3024498 (Block 4); 
wheeze, any wheezy symptoms in the first 3 years of life; x, homozygous carrier of the respective SNP/deletion 
(Liu and Raedler et al. 2011). 
 
 
 
 
Homozygous carriers of all SNPs (diplotype 3) showed besides a higher AD prevalence also an 
increase in the wheeze prevalence from 39.1% (diplotype 0) to 70%. 
Both, genetic variations in Toll-like receptors and IL-10 already had an impact on the neonatal 
immune regulation. TLR2 SNPs affected gene expression of Treg marker genes, modulated by 
the atopy status of the mother. IL-10 SNPs also influenced Treg-marker gene expression and 
besides Th1, Th2 and pro-inflammatory cytokine secretion. Both polymorphisms in TLR2 and 
Diplo- 
type 
SNP SNP SNP SNP SNP SNP SNP-pattern wheeze AD AD/wheeze 
1 2 3 4 5 6 N % n/N % n/N % n/N % 
0 - - - - - - 125 76.7 43/110 39.1 32/109 29.4 57/109 52.3 
1 - - - x x - 11 6.8 3/10 30.0 3/10 30.0 5/10 50.0 
2 - x x x x - 10 6.1 2/9 22.2 5/9 55.6 6/9 66.7 
3 x x x x x x 10 6.1 7/10 70.0 5/10 50.0 9/10 90.0 
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IL-10 were associated with development of immune-mediated diseases such as atopic 
dermatitis and wheeze in early childhood. 
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3.3 Immune regulation during the manifestation of childhood asthma 
In the first part of this thesis we investigated the influence of genetic variants on immune 
regulation in cord blood and could already detect an association of early immune maturation 
with a later development of wheeze and atopic diseases at age 3 years. In the second part, 
immune regulation later in childhood, namely during the manifestation of childhood asthma 
was investigated. The aim was to identify the immunological mechanisms which contribute to 
the pathophysiology of allergic and non-allergic asthma, the two main clinical asthma 
phenotypes in childhood (Raedler et al., manuscript in preparation). 
For this purpose, we assessed several dimensions of immune regulation: We studied different T 
helper cell subsets with a special focus on Tregs and Th17 cells. Besides a quantification of 
both cell types, we assessed suppressive capacity of Tregs and determined cytokine levels of 
further Th cell subsets. Gene expression was assessed genome-wide and on single gene level. 
To study the impact of epigenetic regulation on childhood asthma, we assessed the methylation 
status genome-wide and furthermore methylation and acetylation of single candidate genes. To 
study the role of genetics on allergic and non-allergic asthma in childhood, the study 
population was genotyped for 108 polymorphisms, including the TLR2 and IL-10 SNPs, which 
were reported to be associated with development of atopic disease and wheeze within the first 
part of this thesis. 
From this comprehensive assessment of immune regulation, the main findings are presented in 
the following, whereas genome-wide methylation analysis and genotyping are currently 
performed and not yet included in the results below. 
 
3.3.1 Characterization of the CLARA study population 
 
From January 2009 on we recruited a study population of currently 236 children, while 
recruitment is still ongoing. Asthmatics were defined by at least 3 attacks of obstructive 
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bronchitis and/or a doctor´s diagnosis of recurrent episodes of obstructive bronchitis and/or a 
history of asthma medication and a typical lung function showing reversible pulmonary 
obstruction. The classification in allergic and non-allergic asthma was based on positive or 
negative specific allergic sensitization assessed by RAST test, respectively. 
196 children from the CLARA population were included for this analysis, comprising 73 AA, 
13 NA and 81 healthy children (HC). 12 children were excluded due to further pulmonary or 
autoimmune diseases or infections. 4 children suffered from allergy without asthma. 13 
children showed an overlap of phenotypes and were not included.  
Regarding phenotypic differences, eosinophils, IgE, FeNO and delta FEV1 were significantly 
different between the three groups, clearly delineating the three phenotypes (Table 9).  
 
Table 9: Clinical parameters of the CLARA study population 
 
 
 
 
 
 
 
 
 
 
 
HC, healthy controls; AA, allergic asthmatics; NA, non-allergic asthmatics; N, number of cases (+ diagnosis to be 
confirmed); IgE, Immunglobulin E; FENO, fraction of exhaled nitric oxygen; AHR, airway hyperresponsiveness; 
∆FEV1, difference of forced expiratory volume in 1 second before and after bronchodilatation; p-value [KW], p-
value from Kruskal-Wallis test; data presented as mean (± standard error of the mean). 
 
 
 
AA had significantly increased eosinophils, total IgE and exhaled nitric oxygen. Allergic and 
non-allergic children showed increased airway hyperresponsiveness (>10 %), determined by 
lung function tests before and after bronchodilatation with the short-acting β2-adrenergic 
receptor agonist salbutamol. Detailed population characteristics are depicted in Table 10.  
 
Phenotype 
HC AA NA 
p-value 
[KW] Parameter 
N 81 73 (+12) 13 (+1)  
Eosinophils [%] 2.8 (0.25) 8.1 (0.54) 5.3 (1.2) <0.0001 
IgE [IU/ml] 81.2 (13.7) 729.4 (140.8) 82.6 (20.1) <0.0001 
FENO [ppg] 8.6 (2.1) 51.1 (5.9) 11.6 (3.9) <0.0001 
AHR (∆FEV1) 4.5 (1.3) 13.0 (0.8) 11.9 (1.1) <0.0001 
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Table 10: Population characteristics of the CLARA study population 
 
Parameter HC (n=81) AA (n=73) NA (n=13) p-value 
Female sex, n (%) 35 (43.21) 23 (31.51) 7 (53.85) 0.171 
Age (years), mean ±SD 10.0±3.1 9.3±3.1 7.5±1.8 0.004 
Maternal diagnosis of asthma 
(ever), n (%) 
5 (7.89) 10 (13.89) 2 (15.38) 0.231 
Maternal diagnosis of hay fever 
(ever), n (%) 
17 (22.37) 21 (29.17) 0 (0) 0.051 
Paternal diagnosis of asthma 
(ever), n (%) 
6 (7.89) 11 (15.07) 1 (7.69) 0.378 
Paternal diagnosis of hay fever 
(ever), n (%) 
17 (22.37) 19 (26.03) 1 (7.69) 0.416 
Smoking at home, n (%) 16 (20.51) 5 (6.85) 4 (30.77) 0.012 
Maternal education, (%)  
     Elementary school 17.95 19.40 46.15 0.085 
     Middle school 30.77 14.93 23.08  
     High school 24.36 19.4 15.38  
     University 23.08 40.30 7.69  
     other 3.84 5.85 7.69  
Paternal education, (%)  
     Elementary school 22.37 20.9 46.15 0.005 
     Middle school 22.37 4.48 7.69  
     High school 21.05 20.9 30.77  
     University 30.26 50.75 7.69  
     No/other 3.95 2.99 7.69  
 
 
The three groups differed significantly in their age, with the lowest mean age in NA. The 
number of younger and older siblings did not differ between the three phenotypes (not shown).  
The three phenotypes differed significantly regarding age, maternal diagnosis of hay fever, 
smoking at home and paternal education. All analyses did not significantly change after 
adjusting for the potential confounders and are consequently presented unadjusted. 
 
3.3.2 Immune signature of allergic and non-allergic asthmatics in regards to Treg and 
Th17 cells, gene expression, protein secretion and epigenetic regulation 
 
To better characterize allergic and non-allergic asthmatics and to understand the underlying 
pathophysiology, we investigated different T helper cell subsets with a special focus on Tregs 
and Th17 cells, suppressive capacity of Tregs, cytokine levels of further Th cell subsets, gene 
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expression on genome-wide and on single gene level and epigenetic regulation by analysing 
methylation and acetylation of single candidate genes, at the manifestation of disease. 
 
3.3.2.1 Immune signature of allergic asthmatics 
 
As previous results from our group on cord blood immune regulation already indicated an 
important role for Tregs in development of asthma later in life (Schaub et al. 2009), we were 
interested in the role of Tregs in development of allergic and non-allergic asthma in children 
age 4 to 15 years within this study. By quantification via flow cytometry, we detected 
increased numbers of Tregs in asthmatics and especially in allergic asthmatics, yet differences 
were only significant in the comparison with HC (Figure 8 A-C,E). To quantify Tregs, we 
analysed the CD4
+
CD25
+
 cells that were additionally either positive for the Treg TF FOXP3 
(Figure 8A) or negative for the -chain of the integrin VLA-4 (CD49d) (Figure 8B). The 
absence of CD49d was suggested as further Treg marker by Kleinewietfeld et al. 
(Kleinewietfelt et al. 2010).  
To objectively quantify Treg cells, CD4
+
CD25
high
 cells were defined as the upper 10% of 
CD4
+
CD25
+
 (CD4
+
 up.10%CD25
+
). In Figure 8C and 8D, the FOXP3
+
 and CD49d
-
 negative 
cells within the upper 10% of CD4
+
CD25
+
 cells are depicted. The CD4
+
CD25
+ 
cells, positive 
for FOXP3 and in parallel negative for CD49d (CD4
+
CD25
+
FOXP3
+
CD49d
-
) are depicted in 
Figure 8E. 
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From a subgroup of samples we determined gene expression of the Treg transcription factor 
FOXP3 and of GARP, which is specifically expressed on Tregs, by qRT-PCR. FOXP3 and 
GARP mRNA were significantly increased in AA compared to HC (Figure 9A/B, both p=0.03) 
and FOXP3 showed a trend for highest expression in AA compared to HC and NA independent 
of the stimulation condition, here entitled as “main effect” (Figure 9C, main effect, 
p=0.10/0.09). 
These results were additionally confirmed by microarray experiments, showing significant 
higher expression of FOXP3 and CD25 in unstimulated PBMCs of AA vs. HC (not shown, 
Figure 8. Treg numbers in unstimulated PBMCs. 
Tregs were assessed by flow cytometry. Distribution of the 
cells relative to lymphocytes (%) (A/B/E) and relative to upper 
10% of CD4
+
CD25
+
 cells (C/D). Parameters include surface 
markers (CD4, CD25, CD49d) and intracellular FOXP3. 
n(HC)=57, n(AA)=61, n(NA)=11; p-value from ANOVA on 
log transformed data.Data are depicted as boxplots (first/third 
quartile, median, whiskers indicate the maximum and minimum 
values, dots represent outliers; black line indicates the 
geometric mean) (Raedler et al., manuscript in preparation). 
A. B.
C. D.
E.
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p=0.001/0.02) and significantly higher FOXP3 and GITR levels in AA compared to NA (both 
p=0.02). 
 
 
 
Figure 9. mRNA expression of FOXP3 and GARP in HC, AA and NA.  
(A) Expression of FOXP3 and (B) GARP mRNA following LpA-stimulation; (C) FOXP3 mRNA expression, 
independent of the stimulation condition (main effect); mRNA expression was assessed by qRT-PCR, PCR data 
depicted as median +/- CI ∆CT values; higher values reflect lower expression (axis vice versa); n(HC)=15, 
n(AA)=15, n(NA)=10; p-value from tobit on ranks analysis (Raedler et al., manuscript in preparation). 
 
 
FOXP3 demethylation in the Treg-specific demethylated region (TSDR) has been suggested as 
a novel and specific marker for natural Tregs in adults (Baron et al. 2007). Within our study, 
TSDR demethylation was assessed in PBMCs without and following anti-CD3/CD28-
stimulation. The amount of Treg cells, determined by Epiontis via TSDR demethylation 
analysis, was increased in AA compared to HC without and following stimulation (Figure 
10A/B, p=0.24/0.06). The number of Tregs did not significantly differ before and after anti-
CD3/28-stimulation, indicating that TSDR demethylation is a specific marker for nTregs but 
not induced Tregs and activated T cells. 
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In order to assess if the expression of FOXP3 was regulated by epigenetic mechanisms, we 
determined the acetylation status of the two histon proteins H3 and H4 in unstimulated CD4
+
 
cells (Figure 10C). Histon acetylation alters nucleosomal conformation and thereby increases 
the accessibility of transcriptional regulatory proteins to the chromatin template and results in 
higher levels of transcription (Struhl K, 1998). FOXP3 acetylation at the histon protein H4 did 
not differ between AA and HC, while acetylation was increased at H3 in AA compared to HC, 
indirectly indicating a higher transcription rate of FOXP3 in AA (Figure 10C, p=0.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. FOXP3 TSDR demethylation and histon acetylation in HC and AA.  
Number of nTregs [%] in PBMCs, determined by TSDR demethylation in (A) unstimulated and (B) anti-CD3/28-
stimulated PBMCs, shown as mean±SD; n(HC)=11, n(AA)=11. (C) FOXP3 acetylation at histone H3 (AcH3) 
and H4 (AcH4) in unstimulated CD4
+
 cells. Data shown as percent enrichment to input controls, depicted as 
boxplots (first/third quartile, median, whiskers indicate the maximum and minimum values, dots indicate 
outliers); n(HC)=15, n(AA)=9; p-value from Mann-Whitney test. 
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Quantification data from flow cytometry, qRT-PCR and microarray experiments suggest a 
higher amount of regulatory T cells in allergic asthmatics compared to non-allergic asthmatics 
and healthy children. By analysis of the methylation status of the Treg-specific demethylated 
region in AA and HC, the number of nTregs was confirmed to be increased in AA compared to 
HC, yet data were not significant. Expression of the Treg master regulator FOXP3 was 
increased in AA, which might partially be explained by an increased histone H3 acetylation 
compared to HC.  
 
While FOXP3
+
 Tregs were reported to suppress aberrant immune responses and thereby 
contribute to the maintenance of immune tolerance and homeostasis, Tregs were increased in 
the AA phenotype. As this phenotype is characterized by allergic inflammation, Tregs may not 
be able to suppress the “excessive” immune reactions. To test the hypothesis that Treg function 
is impaired in AA, we analysed the suppressive capacity of Tregs in a subgroup of 11 AA and 
10 HC and determined the effect of Tregs on cell division of effector cells (Figure 11) and the 
Treg suppressive capacity (Figure 12). 
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Figure 11. Cell divison of CFSE-stained effector T cells with increasing amounts of Tregs.  
Cell division of PHA-stimulated effector cells (CD4
+
CD25
-
) without Tregs (ratio Teffs:Tregs = 1:0) and with 
Tregs (Teffs:Tregs = 1:0.1, 1:0.25, 1:5, 1:1, 1:2), shown as mean±SD; p-value from linear mixed model; 
n(HC)=10, n(AA)=11.       
 
 
 
Without Tregs about 50% of the CFSE-stained Teffs have divided after 72h of incubation. 
Addition of Tregs from both HC and AA was able to approximately half effector cell division 
at the ratio of Teff:Tregs = 1:0.1, whereas the decrease in cell division was more efficient with 
increasing numbers of Tregs (Figure 11, all p≤0.0001). The suppressive capacity of Tregs in 
AA was decreased compared to HC, however this effect was not significant (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.……….... 
Suppressive capacity 
of Tregs of HC vs. 
AA.  
Suppressive capacity [SC] 
of Tregs; ratio 
Teffs:Tregs, ratio of 
effector cells to Tregs 
(1:0.1, 1:0.25, 1:0.5, 1:1, 
1:2), shown as mean±SD; 
p-values from linear 
mixed model; n(HC)=10, 
n(AA)=11.      
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To investigate the underlying suppressive mechanism, we measured cytokines in the 
supernatants of PHA-stimulated effector cells alone and in coculture with Treg cells. 
Following addition of Tregs, cytokine levels of IL-5, IL-9, IL-13 and IFN-were significantly 
decreased in both HC and AA, however levels did not significantly differ between the two 
phenotypes before and after addition of Tregs, respectively (Figure 13, A/B/D/E, all p≤0.007). 
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Cytokine regulation before and after Treg suppression was significantly different in both, HC 
and AA. However, the ratio of Th2/Th1 cytokines was significantly decreased in Teffs after 
Treg suppression only of HC but not AA (Figure 14, p=0.03).  
Figure 13. Cytokine levels in Treg suppression assay 
supernatants of AA and HC in presence or absence 
of Tregs. Cytokine secretion [pg/ml] of (A) IL-9, (B) IFN-, (C) 
IL-5, (D) IL-2, (E) IL-13, (F) IL-10, (G) IL-1 depicted as 
boxplots (first/third quartile, median, whiskers indicate the 
maximum and minimum values, dots indicate outliers); 
Teffs:Tregs 1:0.5; p-values from tobit analysis on log transformed 
data comparing cytokine secretion in supernatants of HC and AA 
without (-) Tregs and after addition of Tregs (+); n(HC)=10, 
n(AA)=11.      
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Figure 14. IL-5/IL-2 (Th2/Th1) cytokine ratio in Treg suppression assay supernatants 
of AA and HC in presence or absence of Tregs. Teffs:Tregs = 1:0.5; p-values from linear mixed 
model; cytokine ratio depicted as boxplots (first/third quartile, median, whiskers indicate the maximum and 
minimum values, dots indicate outliers); n(HC)=10, n(AA)=11.      
 
 
 
 
Children with AA were consequently characterized by an increase in Tregs with lower 
suppressive capacity for IL-5/IL-2 cytokine secretion. 
 
3.3.2.2 Immune signature of non-allergic asthmatics 
 
Highest levels of pro-inflammatory IL-1 protein levels were detected in NA. Levels were 
increased in NA compared to HC (Figure 15A-C, p(Media)=0.05; p(LpA)=0.003; 
p(Ppg)=0.07) and in NA compared to AA without stimulation (Figure 15A, p=0.09). IL-1 
mRNA expression was significantly increased in NA compared to HC (Figure 15D, 
p(LpA)=0.03). 
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Figure 15. Pro-inflammatory IL-ß secretion and mRNA expression in HC, AA and NA. 
Protein levels of IL-1 following (A) no stimulation, (B) LpA-stimulation, (C) Ppg-stimulation; protein data 
depicted as boxplots (first/third quartile, median, whiskers indicate the maximum and minimum values, dots 
indicate outliers); n(HC)=72, n(AA)=60, n(NA)=11. (D) IL-1 mRNA expression (LpA). PCR data presented as 
median +/- CI ∆CT values. Higher values reflect lower expression (axis vice versa); n(HC)=29, n(AA)=29, 
n(NA)=10 (Raedler et al., manuscript in preparation). 
 
 
 
While pro-inflammatory IL-1 was up-regulated in NA, the anti-inflammatory cytokine IL-37 
was up-regulated in parallel within all stimulation conditions and significantly following anti-
CD3/CD28-stimulation (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. IL-37 mRNA expression 
following anti-CD3/28-stimulation. 
PCR data shown as median +/- CI ∆CT values. 
Higher values reflect lower expression (axis vice 
versa); n(HC)=29, n(AA)=29, n(NA)=10 (Raedler 
et al., manuscript in preparation). 
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While there was a trend for higher numbers of IL17
+
CD4
+
 cells detectable in AA compared to 
HC, there were no differences within the two asthma phenotypes (data not shown; p(M)=0.09, 
p(CD3/28)=0.06). At cytokine level, IL-17 protein was significantly different among HC, AA 
and NA following adaptive and innate stimulation (Figure 17, p=0.001/0.007). IL-17 was 
increased in asthmatics compared to HC, however did not differ significantly within AA and 
NA. 
 
 
Figure 17. IL-17 cytokine levels in HC, AA and NA.   
Protein levels of IL-17 following (A) anti-CD3/CD28- and (B) LpA-stimulation. Cytokine data depicted as 
boxplots (first/third quartile, median, whiskers indicate the maximum and minimum values, dots indicate outliers); 
n(HC)=72, n(AA)=60, n(NA)=11; p-value from tobit analysis on log transformed data (Raedler et al., manuscript 
in preparation). 
 
 
 
 
A comparison of ratios of the characteristic Th17 cytokine IL-17 to pro-inflammatory, Th2 and 
Th1 cytokines revealed a Th17-shifted profile with highest ratios in NA compared to AA and 
HC (Figure 18). The ratios of IL-17 to IL-4, IL-13, IFN-, IL-1 and TNF- were significantly 
increased in NA compared to HC (Figure 18A/C-F, all p<0.02). The ratio of IL-17/IFN- was 
significantly increased in NA compared to AA (Figure 18D, p=0.009). 
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Figure 18. Cytokine ratios of IL-17 to Th2, Th1 and pro-inflammatory cytokines.    
Cytokine ratios of IL-17 to the Th2 cytokines (A) IL-4 (LpA), (B) IL-5 (CD3/CD28), (C) IL-13 (LpA), (D) the 
Th1 cytokine  IFN- (LpA), the pro-inflammatory cytokines (E) IL-1 (CD3/CD28) and (F) TNF- 
(CD3/CD28), depicted as boxplots (first/third quartile, median, whiskers indicate the maximum and minimum 
values, dots indicate outliers); n(HC)=72, n(AA)=60, n(NA)=11, p-values from linear models (Raedler et al., 
manuscript in preparation). 
 
 
 
Moreover, neutrophil counts in whole blood differed within the three phenotypes, with a higher 
percentage in NA compared to HC and AA (Figure 19, p=0.06/0.03). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Percentage of neutrophils in whole blood of HC, AA and NA. 
p-value from Kruskal-Wallis (3 groups) and  Mann-Whitney test (2 groups); data depicted as boxplots 
(first/third quartile, median, whiskers indicate the maximum and minimum values, dots indicate outliers);  
n(HC)=84, n(AA)=74, n(NA)=13 (Raedler et al,. manuscript in preparation). 
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3.3.2.3 Shared immunological profile of allergic and non-allergic asthmatics 
 
As the pathogenesis of allergic asthma is believed to be in part mediated by an inadequate and 
excessive Th2 response (Kiley et al. 2007), we compared the Th2 cytokines IL-5 and IL-13 in  
AA, NA and HC. IL-5 and IL-13 concentrations differed significantly or trendwise among the 
three phenotypes (Figure 20). AA and NA shared a Th2-biased phenotype, as IL-5 levels were 
not only significantly increased in AA compared to HC (Figure 20A/B, p(M)=0.03, 
p(LpA)<0.001) but also showed increased levels in NA compared to HC (Figure 20A-C, 
p(M)=0.08, p(LpA)=0.001, p(Ppg)=0.10). For LpA- and Ppg-stimulation, IL-5 levels were 
highest in NA, yet did not significantly differ from AA. The Th2 cytokine IL-13 was 
significantly increased in AA compared to HC following anti-CD3/CD28-stimulation (Figure 
20D, p=0.003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Th2 cytokine levels in HC, AA and NA.   
Protein levels of IL-5 following (A) no stimulation, (B) LpA-stimulation, (C) Ppg-stimulation; (D) IL-13 protein 
level following anti-CD3/CD28-stimulation. n(HC)=72, n(AA)=60, n(NA)=11. Cytokine data are depicted as 
boxplots (first/third quartile, median, whiskers indicate the maximum and minimum values, dots indicate outliers); 
p-value from Tobit analysis on log transformed data (Raedler et al., manuscript in preparation). 
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Concentrations of the characteristic Th1 cytokine IFN- were highest in HC, but did not differ 
significantly in the three-group comparison of HC, AA and NA. IFN- levels were trendwise 
increased in HC compared to NA (Figure 21A/B, p=0.10/0.07) and were borderline significant 
decreased in NA compared to AA following LpA-stimulation (Figure 21A, p=0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. IFN- cytokine levels in HC, AA and NA.   
Protein levels of IFN- following innate stimulation with (A) LpA or (B) Ppg. Cytokine data are depicted as 
boxplots (first/third quartile, median, whiskers indicate the maximum and minimum values, dots indicate outliers); 
n(HC)=72, n(AA)=60, n(NA)=11; p-value from tobit analysis on log transformed data (Raedler et al., manuscript 
in preparation). 
 
 
 
As epigenetics were reported to be involved in T cell differentiation (Lee et al. 2006), we 
furthermore investigated IFN-promoter methylation and histon acetylation. Especially the 
IFN- locus was shown to undergo epigenetic changes during differentiation, which strongly 
control IFN- gene expression (White et al. 2006). 
In cooperation with the group of Prof. Dr. Harald Renz in Marburg, we investigated the 
methylation status of 3 CpG sites in the proximal IFN- promoter, which were located 
downstream (+119, +125, +168) of the transcription start site (Figure 22).  
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Figure 22. CpG methylation of the IFN- promoter in isolated CD4+ cells.  
Data presented as mean percentage of methylation ± SD at 3 CpG sites downstream (+) of the transcription start 
site (0); n(HC)=21, n(AA)=17, n(NA)=6; p-values from ANOVA analysis; n.s., not significant. 
 
 
No significant differences in the methylation status of the analysed region within the IFN- 
promoter were observed between HC, AA and NA. Additionally, we studied IFN- histone 
acetylation, a further epigenetic mechanism which was, especially in mouse models, shown to 
be closely associated with IFN- mRNA expression (Brand et al. 2011) (Figure 23). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. IFN- histone H3 and H4 acetylation in isolated CD4+ cells.  
IFN acetylation at histone H3 (AcH3) and H4 (AcH4) in unstimulated CD4+ cells. Data shown as percent 
enrichment to input controls, depicted as boxplots (first/third quartile, median, whiskers indicate the maximum 
and minimum values, dots indicate outliers); n(HC)=15, n(AA)=9; p-value from Mann-Whitney test.  
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Acetylation of H3 and H4 did not differ between HC and AA (Figure 23). 
In summary, the Th2 cytokines IL-5 and IL-13 were increased in asthmatics, while the Th1 
cytokine IFN- was decreased (not significant). This decrease in IFN- was not mediated via 
epigenetic regulation by methylation or acetylation. Neither Th2 cytokines, nor the Th1 
cytokine IFN- could help to clearly discriminate between the two asthmatic phenotypes.  
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3.4 Allergic and non-allergic childhood asthma: Identification of novel differentially 
regulated biomarker genes and pathways by microarray analysis   
 
To be able to better characterize the two childhood asthma phenotypes we studied genome-
wide gene expression and regulation applying microarray technology. The intention was to find 
differentially regulated genes and pathways within the three phenotypes that could serve as 
potential biomarkers and help to better understand the underlying pathophysiological 
mechanisms in allergic and non-allergic asthma. 
 
 
3.4.1 Differentially expressed genes within allergic asthmatics, non-allergic asthmatics and 
healthy children 
 
In order to identify differentially expressed genes that can contribute to better immunologically 
distinguish between HC, AA and NA, gene expression was investigated in PBMCs and isolated 
CD4
+
 cells.  In Figure 24, the differentially expressed genes within the three 2-group 
comparisons are depicted for PBMCs. 
 
 
 
 
 
 
 
Figure 24. Differentially expressed genes within AA, NA and HC.  
(A) Venn diagramm of the contrasts showing the numbers of differentially expressed genes; intersections are 
given in the overlapping circles. (B) Cluster analysis of significantly differential expressed genes is displayed in a 
heatmap (Raedler and Da Costa et al., manuscript in preparation). 
 
 
 
Table 11 depicts the top 100 significantly up-/down-regulated genes in each of the 3 two-group 
comparisons, independent of the stimulation condition (main effect). 
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Table 11: Top 100 genes from microarray 2-group comparisons (part I) 
 
 AA vs. HC NA vs. HC NA vs. AA 
Nr. Aff. ID Gene logFC adj.P.Val Aff. ID Gene logFC adj.P.Val Aff. ID Gene logFC adj.P.Val 
1 8089249 RPL24 -0.749 2.3E-11 7954310 RN18S1 -1.395 5.6E-05 7994371 LOC100132247 -0.930 1.3E-04 
2 8071920 SNRPD3 -0.679 3.0E-10 7940070 C11orf31 -0.276 2.4E-04 7898988 CLIC4 0.475 9.0E-04 
3 8165309 EDF1 -0.585 3.0E-10 8086752 SNORD13 1.491 3.4E-04 8166072 TMSB4X 0.260 1.2E-03 
4 7912670 UQCRH -0.588 1.3E-09 8034512 SNORD41 1.466 3.4E-04 7904469 SRGAP2 0.389 1.2E-03 
5 8077663 JAGN1 -0.414 1.8E-09 8138647 C7orf31 0.286 3.5E-04 8133442 LAT2 0.380 1.4E-03 
6 8082911 NCK1 -0.417 1.9E-09 8065359 CD93 0.693 3.8E-04 8112746 WDR41 0.383 1.5E-03 
7 7989611 FAM96A -0.461 2.4E-09 8145793 SNORD13 1.248 3.8E-04 7926677 OTUD1 0.468 1.5E-03 
8 8043100 TMSB10 -0.459 3.0E-09 7907830 QSOX1 0.441 3.8E-04 7912040 TNFRSF25 -0.375 3.7E-03 
9 8166072 TMSB4X -0.310 3.6E-09 8073194 GRAP2 -0.369 3.8E-04 8043100 TMSB10 0.354 3.7E-03 
10 8050695 SF3B14 -0.446 4.6E-09 8092905 LSG1 -0.396 3.8E-04 8075182 XBP1 0.349 3.7E-03 
11 8040036 RPS7 -0.457 1.3E-08 7974066 PNN -0.279 3.8E-04 8089249 RPL24 0.496 3.7E-03 
12 7936727 RPL21 -0.497 2.4E-08 8044961 RNU4ATAC 1.090 3.8E-04 7899480 SNORA73A 0.549 3.7E-03 
13 7898875 RPL11 -0.442 2.4E-08 7952056 CD3D -0.369 4.1E-04 8134777 PVRIG -0.359 4.0E-03 
14 8063903 RPS21 -0.531 3.8E-08 8156610 HABP4 -0.348 9.7E-04 8172358 UXT 0.274 4.3E-03 
15 8131661 RPL21 -0.527 4.9E-08 8030362 SNORD33 0.756 9.7E-04 8073194 GRAP2 -0.327 4.6E-03 
16 8126952 WTAP -0.311 9.4E-08 7922040 CD247 -0.355 1.2E-03 8121886 HINT3 0.361 4.7E-03 
17 8131949 CBX3 -0.293 1.0E-07 8073603 RNU12 0.581 1.2E-03 7935337 PIK3AP1 0.423 4.9E-03 
18 8143957 RHEB -0.512 1.1E-07 7905171 PRPF3 -0.279 1.2E-03 7915101 INPP5B 0.342 4.9E-03 
19 8086698 CCDC12 -0.394 1.1E-07 8060503 SNORD57 0.920 1.2E-03 7959023 MAP1LC3B2 0.291 5.0E-03 
20 7915733 PRDX1 -0.442 1.4E-07 7914887 TRAPPC3 -0.263 1.2E-03 8152222 AZIN1 0.298 5.6E-03 
21 8049574 UBE2F -0.457 1.5E-07 7935337 PIK3AP1 0.441 1.2E-03 7981290 WARS 0.513 5.6E-03 
22 8020149 NAPG -0.424 1.5E-07 8041168 SNORD53 0.716 1.7E-03 7961900 ITPR2 0.364 5.6E-03 
23 7983606 EID1 -0.331 1.6E-07 8093039 SDHAP1 -0.290 1.9E-03 8020149 NAPG 0.349 5.6E-03 
24 7972044 COMMD6 -0.454 1.6E-07 8030199 SNRNP70 -0.289 1.9E-03 8166442 FAM3C 0.285 6.0E-03 
25 8024194 GPX4 -0.335 1.7E-07 7914216 SNORA16A 0.934 1.9E-03 7911730 PANK4 -0.222 6.0E-03 
26 8023063 ATP5A1 -0.370 1.7E-07 7902235 LRRC7 0.199 2.0E-03 8002322 PDXDC2P -0.350 6.0E-03 
27 7943158 SCARNA9 -0.756 1.8E-07 8139411 TMED4 -0.212 2.2E-03 8093294 CCR2 0.952 6.4E-03 
28 8020898 ZNF271 -0.324 1.8E-07 8066262 SNORA71D 0.790 2.3E-03 8137264 TMEM176A 1.082 6.6E-03 
29 7925691 ZNF124 -0.373 2.1E-07 7921237 FCRL5 0.807 2.3E-03 7905571 S100A9 0.762 6.6-03 
30 8005877 RPS7 -0.439 2.2E-07 8059854 ARL4C -0.423 2.3E-03 7989611 FAM96A 0.321 6.6E-03 
31 8164067 PSMB7 -0.386 2.7E-07 7948902 SNORD29 0.771 2.6E-03 7924309 ESRRG -0.175 6.6E-03 
32 7911568 SSU72 -0.347 2.7E-07 8116297 HNRNPH1 -0.180 2.7E-03 8140433 POMZP3 -0.286 6.9E-03 
33 8017421 CCDC47 -0.373 2.8E-07 8084917 LOC440993 -0.530 2.8E-03 7948894 RNU2-1 0.914 6.9E-03 
34 8036710 GMFG -0.304 2.9E-07 8023392 SNORA37 0.720 2.8E-03 8049574 UBE2F 0.364 6.9E-03 
35 8042052 RPS27A -0.496 3.0E-07 7934215 SPOCK2 -0.327 2.8E-03 8023043 PSTPIP2 0.628 6.9E-03 
36 8110415 SUDS3 -0.412 3.1E-07 8025584 SNORD105 0.904 2.9E-03 7915468 CCDC23 0.569 6.9E-03 
37 7983274 PDIA3 -0.345 3.2E-07 8096669 TET2 0.258 2.9E-03 8044417 TMEM87B 0.273 6.9E-03 
38 8034021 CDC37 -0.331 3.2E-07 8126303 TREM1 0.908 2.9E-03 8050352 NTSR2 -0.215 6.9E-03 
39 8152096 YWHAZ -0.280 3.3E-07 7905571 S100A9 0.777 3.0E-03 8023450 TXNL1 0.247 6.9E-03 
40 8086752 SNORD13 1.445 3.4E-07 7995539 NOD2 0.384 3.0E-03 8000537 PDXDC2P -0.316 6.9E-03 
41 8145793 SNORD13 1.235 4.1E-07 8030360 SNORD32A 0.845 3.2E-03 8023246 C18orf32 0.220 7.1E-03 
42 8085263 TMEM111 -0.416 4.2E-07 7981242 BCL11B -0.361 3.5E-03 8143790 TMEM176B 0.943 7.3E-03 
43 7903582 RPL17 -0.299 4.3E-07 7918869 NGF 0.217 3.7E-03 8158240 TMSB4X 0.227 7.3E-03 
44 8006812 PSMB3 -0.400 4.3E-07 8103508 MARCH1 0.511 3.8E-03 7912343 CASZ1 -0.343 7.6E-03 
45 8148263 TRMT12 -0.402 4.3E-07 8164607 FNBP1 -0.184 4.0E-03 8011826 C17orf87 0.816 7.6E-03 
46 8163930 NDUFA8 -0.434 4.5E-07 8066258 SNORA71A 0.689 4.0E-03 7945132 FLI1 0.203 8.2E-03 
47 7964076 CNPY2 -0.382 4.6E-07 7932530 PIP4K2A -0.246 4.0E-03 7924144 RPL21P28 0.533 8.3E-03 
48 8172358 UXT -0.302 5.1E-07 8053775 ZNF514 -0.365 4.0E-03 8017186 HEATR6 0.348 8.3E-03 
49 7978201 NEDD8 -0.329 6.2E-07 8131996 CREB5 0.340 4.0E-03 7921237 FCRL5 0.741 8.3E-03 
50 8023855 CYB5A -0.398 6.5E-07 7915612 PTCH2 0.758 4.0E-03 8068593 ETS2 0.476 8.3E-03 
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Table 11: Top 100 genes from microarray 2-group comparisons (part II) 
 
Aff. ID, Affymetrix gene ID; logFC, log2-fold change; adj.P.Val, adjusted p-value. Genes chosen for confirmation 
by qRT-PCR printed in boldface (Raedler and Da Costa et al. Manuscript in preparation). 
 AA vs. HC NA vs. HC NA vs. AA 
Nr. Aff. ID Gene logFC adj.P.Val Aff. ID Gene logFC adj.P.Val Aff. ID Gene logFC adj.P.Val 
51 7936091 USMG5 -0.553 6.9E-07 7973221 TRAJ17 -0.321 4.5E-03 7992463 SLC9A3R2 -0.225 8.3E-03 
52 7955817 PCBP2 -0.247 6.9E-07 8117746 SNORD32B 0.437 4.6E-03 7976243 CPSF2 0.258 8.3E-03 
53 8029969 SEPW1 -0.342 6.9E-07 8011499 P2RX1 0.436 4.7E-03 8071392 MED15 -0.213 8.3E-03 
54 7978754 C11orf58 -0.322 7.2E-07 8158829 BAT2L1 -0.228 4.7E-03 8154785 CHMP5 0.463 8.3E-03 
55 7920873 SNORA42 0.975 7.4E-07 7908397 RGS13 0.178 5.1E-03 8102214 PAPSS1 0.374 8.3E-03 
56 7924144 RPL21P28 -0.639 7.6E-07 8061364 RPL41 0.388 5.2E-03 8113433 EFNA5 -0.211 8.3E-03 
57 8130952 PSMB1 -0.426 7.7E-07 8036479 YIF1B 0.281 5.3E-03 8084917 LOC440993 -0.493 8.3E-03 
58 8063509 C20orf43 -0.233 8.2E-07 7924897 C1orf96 -0.202 5.4E-03 7916862 WLS 0.446 9.2E-03 
59 7975113 CHURC1 -0.400 8.4E-07 7987279 GOLGA8B -0.334 5.5E-03 7919578 JAGN1 -0.328 9.2E-03 
60 8048195 RPL37A -0.323 8.4E-07 8176972 IL9R -0.228 5.7E-03 7946516 SBF2 0.320 9.2E-03 
61 7905171 PRPF3 -0.290 8.4E-07 8010078 SNORD1C 0.893 5.9E-03 7958019 DRAM1 0.615 9.2E-03 
62 8153223 PTK2 -0.335 8.9E-07 7981601 IGHA2 0.332 6.2E-03 7967563 UBC 0.152 9.4E-03 
63 8061772 MAPRE1 -0.260 9.0E-07 7997940 SNORD68 0.907 6.3E-03 8161458 KGFLP2 -0.470 9.4E-03 
64 8173713 MAGT1 -0.269 9.1E-07 8070083 TMEM50B -0.337 6.3E-03 8042391 PLEK 0.595 9.4E-03 
65 8044133 NCK2 0.308 9.1E-07 8093294 CCR2 0.903 6.3E-03 8174076 GLA 0.379 9.4E-03 
66 8094271 MED28 -0.287 9.4E-07 8130578 SNORA20 1.071 6.3E-03 7937287 PSMD13 0.380 1.0E-02 
67 7898894 C1orf128 -0.298 9.6E-07 7911568 SSU72 -0.272 6.3E-03 7943288 SRSF8 -0.216 1.0E-02 
68 8152222 AZIN1 -0.330 9.7E-07 7921298 FCRL2 0.458 6.7E-03 8050695 SF3B14 0.297 1.0E-02 
69 7937476 RPLP2 -0.366 9.7E-07 8018803 SRSF2 -0.225 7.9E-03 7993185 NUBP1 0.319 1.0E-02 
70 7952549 RPUSD4 -0.335 1.1E-06 8161024 RMRP 0.569 8.1E-03 7960280 FBXL14 -0.234 1.0E-02 
71 8079074 SS18L2 -0.281 1.1E-06 7904303 CD101 0.578 8.1E-03 7954055 APOLD1 -0.254 1.0E-02 
72 7970999 SPG20 -0.370 1.1E-06 7981988 SNORD116-20 0.776 8.7E-03 7920244 S100A8 0.958 1.0E-02 
73 8084986 FYTTD1 -0.387 1.2E-06 8009241 SNORD104 0.794 8.7E-03 8033987 ICAM3 0.278 1.0E-02 
74 8171834 RPL9 -0.286 1.2E-06 7975459 SIPA1L1 0.230 8.8E-03 8039905 TMEM167B 0.237 1.0E-02 
75 7906852 UHMK1 -0.280 1.2E-06 8146216 VDAC3 -0.256 9.1E-03 7899361 STX12 0.309 1.1E-02 
76 7979931 MED6 -0.309 1.3E-06 8084904 SDHAP2 -0.250 9.6E-03 7917338 BCL10 0.247 1.1E-02 
77 7904881 PDIA3P -0.383 1.3E-06 7975113 CHURC1 -0.319 1.0E-02 7951030 SNORD6 0.531 1.1E-02 
78 8142878 CDC26 -0.344 1.3E-06 8008087 NFE2L1 0.277 1.0E-02 8179041 HLA-A 0.228 1.1E-02 
79 8124144 DEK -0.384 1.3E-06 8008493 LUC7L3 -0.287 1.1E-02 7952549 RPUSD4 0.273 1.1E-02 
80 8039796 CHMP2A -0.293 1.4E-06 8030860 FPR2 0.782 1.1E-02 7989493 RPS27L 0.258 1.1E-02 
81 8031669 ZNF470 -0.296 1.4E-06 8140196 STAG3L2 -0.201 1.1E-02 7945803 CARS 0.287 1.1E-02 
82 8097782 RPS3A -0.402 2.1E-06 8143188 CREB3L2 0.286 1.1E-02 8161147 HINT2 0.439 1.1E-02 
83 7992987 HMOX2 -0.361 2.3E-06 7898655 CDA 0.642 1.1E-02 8091327 PLSCR1 0.646 1.1E-02 
84 7904948 FAM108A1 0.706 2.3E-06 8142120 NAMPT 0.489 1.1E-02 7953564 C12orf57 0.377 1.1E-02 
85 7935462 EXOSC1 -0.305 2.4E-06 8126018 STK38 -0.292 1.1E-02 7995539 NOD2 0.347 1.2E-02 
86 8017634 DDX5 -0.247 2.4E-06 8016982 SUPT4H1 -0.230 1.1E-02 8028104 HCST 0.419 1.2E-02 
87 8088384 PDHB -0.249 2.4E-06 8003217 COX4NB -0.346 1.1E-02 8048195 RPL37A 0.257 1.2E-02 
88 8042211 B3GNT2 -0.325 2.4E-06 8007803 C17orf69 -0.340 1.1E-02 8057713 MSTN -0.157 1.2E-02 
89 7972810 CARS2 -0.326 2.5E-06 7987449 SRP14 -0.227 1.1E-02 7909175 SRGAP2 0.383 1.2E-02 
90 7942839 PCF11 -0.273 2.5E-06 7906767 FCGR2C 0.752 1.1E-02 8015445 NT5C3L -0.33 1.3E-02 
91 8020919 C18orf21 -0.371 2.6E-06 7953981 ETV6 0.229 1.1E-02 8057394 SESTD1 0.388 1.3E-02 
92 8161242 EXOSC3 -0.394 2.7E-06 7946933 SERGEF -0.210 1.2E-02 8155096 CREB3 0.261 1.3E-02 
93 8089993 WDR5B -0.432 2.7E-06 8102321 PLA2G12A -0.281 1.2E-02 8045499 HNMT 0.406 1.3E-02 
94 8153449 EEF1D -0.247 2.9E-06 8026698 C19orf62 -0.192 1.2E-02 8085660 DPH3 0.297 1.3E-02 
95 8000003 THUMPD1 -0.340 3.0E-06 8133106 SNORA22 1.347 1.2E-02 8121814 NKAIN2 -0.192 1.3E-02 
96 8041168 SNORD53 0.720 3.0E-06 7921319 FCRL1 0.469 1.2E-02 8070826 ITGB2 0.406 1.3E-02 
97 8147228 DECR1 -0.316 3.4E-06 8066260 SNORA71C 0.490 1.2E-02 7992656 AMDHD2 -0.296 1.3E-02 
98 8078834 WDR48 -0.376 3.4E-06 7983606 EID1 -0.239 1.2E-02 7997712 IRF8 0.410 1.4E-02 
99 8138776 HIBADH -0.445 3.8E-06 7950796 CREBZF -0.262 1.2E-02 8030908 ZNF480 -0.327 1.4E-02 
100 8109222 RPL7 -0.338 3.9E-06 8080781 PXK 0.332 1.3E-02 8099850 TMEM156 0.371 1.4E-02 
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From these 300 genes, 13 were chosen for confirmation by qRT-PCR, based on their ranking, 
adjusted p-value and a possible biological role in immune regulatory processes (Table 12). 
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Table 12: Gene selection for validation of microarray gene expression by qRT-PCR  
CCR2, chemokine (C-C motif) receptor 2; CD93, CD93 molecule; CLIC4, chloride intracellular channel 4; 
GMFG, glia maturation factor gamma; HNMT, histamine N-methyltransferase; ICAM3, intercellular adhesion 
molecule 3; IL9R, interleukin 9 receptor; INPP5B, inositol polyphosphate-5-phosphatase; IRF8, interferon 
regulatory factor 8; NOD2, nucleotide-binding oligomerization domain containing 2; S100A9, S100 calcium 
binding protein A9; TREM1, triggering receptor expressed on myeloid cells 1; XBP1, X-box binding protein 1. 
Gene Literature Reference 
CCR2 
o Involved in recruitment and activation of mononuclear cells Zhu et al. 2002 
o Linked to pulmonary fibroblasts and to remodelling diseases of the lung  
CD93 
o Involved in adhesion and clearance of apoptotic cells  
o Inflammation triggers release of sCD93 in vivo Greenlee et al. 2009 
o Regulation of processes involved in innate immunity (angiogenesis,  Greenlee et al. 2008 
phagocytosis of apoptotic cells, tissue repair and homeostasis)  
CLIC4 
o Chloride channel;  regulates stabilization of cell membrane potential  
o Transepithelial transport, maintenance of intracellular pH  
o Regulation of cell volume  
o Positive regulator of LPS signalling He et al. 2011 
o Enhances TGF- signalling Shukla et al. 2009 
GMFG 
o Expressed in inflammatory cells Aerbajinai et al. 2011 
o Regulating neutrophil chemotaxis by modulating actin cytoskeleton   
reorganization  
o Lower expression in asthmatic vs. healthy control airway epithelium Kicic et al. 2010 
HNMT 
o Thr105Ile polymorphism in HNMT gene associated with asthma Szczepankiewicz et al. 2010 
o HNMT plays dominant role in histamine metabolism in human  Yan et al. 2000 
bronchial epithelium   
o Functional SNPs in HNMT decrease its enzyme activity among 
asthmatics 
 
o Histamine involved in pathophysiology of asthma Akagi M., 1998 
ICAM3 
o Expressed by resting T cells; important in first contact with DCs Geijtenbeek et al. 2000 
o Expressed in allergic lung diseases Popper et al. 2002 
IL9R 
o Expressed in asthmatic airways but not in healthy controls  Bhathena et al. 2000 
o Induction of hCLCA1, which has a potential role in mucus  Hauber et al. 2005 
overproduction in asthmatics  
INPP5B 
o Involved in cellular calcium signalling  
o Negative regulator of IgE-Ag-initiated mast cell degranulation Zhang et al. 2010 
IRF8 
o Novel intrinsic transcriptional inhibitor of Th17 cell differentiation Ouyang et al. 2011 
o Important role in differentiation of myeloid cells, promoting monocyte 
over granulocyte differentiation 
 
o Role in inflammatory polarization of macrophages Xu  et al. 2012 
NOD2 
o Role in the immune response to intracellular bacterial 
lipopolysaccharides 
Reijmerink et al. 2010 
o Mutations associated with autoimmune diseases 
o Influences Th1/Th2 balance and thereby modulates the adaptive  
immune response to bacteria 
o Important in the development of atopy and asthma 
S100A9 
o Pro-inflammatory protein, expressed abundantly in the cytosol of 
neutrophils and monocytes 
 
o Increased during early airway response in asthma (rat model of asthma) Yin et al. 2008 
o Amplifier of inflammation in autoimmunity  
o High levels found in Crohn’s disease, rheumatoid arthritis and cystic 
fibrosis 
Simard et al. 2010 
o Regulation of calcium dependent intracellular processes Tirkos et al. 2006 
TREM1 o Amplifies neutrophil- and monocyte-mediated inflammatory responses  Schenk et al. 2007 
XBP1 
o Transcription factor; regulates genes important for immune system Lambrecht and  
o IRE1/XBP-1 pathway is relevant for airway epithelial inflammation- Hammad, 2012 
mediated cytokine secretion  
o TREM-1-activated neutrophils enhance their respiratory burst activity,  Radsak et al. 2004 
degranulation and IL-8 release  
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From these 13 differentially expressed genes, significant differences in mRNA expression could be confimed by qRT-PCR for the genes CD93, 
TREM1, S100A9, CLIC4, INPP5B and IRF8 (Table 13). 
 
Table 13: Comparison of microarray and qPCR results for main effects  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene selection of 13 genes was based on significantly different 2-group comparisons of the microarray analyses; a higher delta CT value (∆CT) refers to a lower gene expression; 
bold p-values, microarray findings that could be confirmed by qRT-PCR; n.s., difference in gene expression assesed by qRT-PCR is not significant (Raedler and Da Costa et al. 
Manuscript in preparation). 
 Microarray qRT-PCR 
 Microarray population Microarray population 
Gene p-value Rank 
2-group 
comparison 
logFC 
p-value 
PCR finding 
2-group 
comparison 
Difference in  
∆CT medians  
GMFG 2.86x10
-7
 34 AA vs. HC -0.30 n.s.   
CD93 
3.80x10
-4
 6 NA vs. HC 0.69 0.002 NA vs. HC -1.68 
0.01 149 NA vs. AA 0.51 9.1 x10
-6
 NA vs. AA -1.79 
TREM1 
2.90x10
-3
 38 NA vs. HC 0.91 0.09 NA vs. HC -1.34 
0.03 346 NA vs. AA 0.71 0.005 NA vs. AA -1.80 
S100A9 
3.00x10
-3
 39 NA vs. HC 0.78 0.01 NA vs. HC -1.14 
5.80x10
-3
 29 NA vs. AA 0.76 0.03 NA vs. AA -0.99 
IL9R 
5.70x10
-3
 88 NA vs. HC -0.23 n.s.   
    0.08 AA vs. HC 0.6 
CCR2 
6.30x10
-3
 65 NA vs. HC 0.90 n.s.   
6.10 x10
-3
 27 NA vs. AA 0.95 n.s.   
CLIC4 
9.30 x10
-4
 2 NA vs. AA 0.48 n.s.   
0.02 5326 AA vs. HC -0.20 0.03 AA vs. HC 1.00 
XBP1 2.30 x10
-3
 10 NA vs. AA 0.35 n.s.   
INPP5B 4.40 x10
-3
 18 NA vs. AA 0.34 0.03 NA vs. AA -0.56 
ICAM3 0.01 73 NA vs. AA 0.28 n.s.   
HNMT 0.01 93 NA vs. AA 0.41 0.10 NA vs. AA -0.73 
IRF8 
0.02 98 NA vs. AA 0.41 0.002 NA vs. AA -0.79  
0.17 13674 AA vs. HC -0.14 0.006 AA vs. HC 0.43 
NOD2 
3.00 x10
-3
 40 NA vs. HC 0.38 n.s.   
0.01 85 NA vs. AA 0.35 n.s.   
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CD93 and TREM1 were confirmed to be up-regulated in NA compared to HC and besides 
showed a significantly increased expression in NA compared to AA (Table 13, p=9.1x10
-6
/
 
0.005, Figure 25A/B/C). S100A9 was significantly higher expressed in NA compared to HC 
and AA (Table 13, both p≤0.03; Figure 25A/D) and IRF8 mRNA expression was significantly 
increased in NA compared to AA and decreased in AA compared to HC (Table 13, both 
p≤0.006; Figure 25A/E). Expression of CLIC4 was decreased in AA compared to HC (Figure 
24A, p=0.03, expression not shown). Expression of INPP5B and HNMT was increased in NA 
compared to AA (Figure 25A/F/G; p=0.03/0.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Confirmation of microarray gene expression results by qRT-PCR.  
Differentially expressed genes assessed by qRT-PCR in the microarray population. Data shown as median +/- CI 
∆CT values. The y-axes are depicted vice-vera as a higher ∆CT refers to a lower gene expression. (A) Venn 
diagramm with three 2-group comparisons; ↑/↓, up-/down-regulation of the gene in the respective 2-group 
comparison(s); gene expression of (B) CD93, (C) TREM1, (D) S100A9, (E) IRF8, (F) INPP5B, (G) HNMT; p-
value from tobit regression on log transformed data; n(HC)=14; n(AA)=14; n(NA)=8. (Raedler and Da Costa et 
al., manuscript in preparation). 
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In summary, the three phenotypes showed distinct gene expression profiles. Expression of 
CD93, TREM1 and S100A9 was significantly increased in non-allergic asthmatic children 
compared to allergic asthmatic and healthy children.  
 
3.4.2 Differentially regulated pathways within allergic asthmatics, non-allergic asthmatics 
and healthy children 
            
Besides single differentially expressed genes, important cellular pathways were investigated by 
GlobalAncova analysis regarding their regulation in AA, NA and HC. Two different sources of 
information were used: First, already annotated cellular pathways from the KEGG pathway 
database, a collection of online databases that connect information on molecular interaction 
networks. Second, characteristic genes of different immune cells including transcription 
factors, cytokines, chemokines and receptors, relevant for the respective cell type (Table 14). 
Significant differences in KEGG pathways and expression of immune cell-characteristic genes 
are shown in Table 15. Differences in regulation of several KEGG pathways were mainly seen 
before and after innate LpA-stimulation. Following anti-CD3/CD28-stimulation, no differences 
were detected except for the TLR and mTOR pathway. mTOR regulation differed significantly 
between AA and HC within all stimulation conditions and between NA and AA after anti-
CD3/CD28-stimulation (Table 15, mTOR, p≤0.03). TGF- signalling differed significantly in 
PBMCs of NA and HC (Table 15; TGF-, Media, p=0.02) and AA compared to HC following 
LpA-stimulation (Table 15, TGF-, p<0.0001; Figure 26). Following innate stimulation, TLR 
signalling differed significantly in AA or NA compared to HC and also among the two asthma 
phenotypes (Table 15, TLR, p=0.02/0.02/0.04). 
Regarding microarray gene expression of characteristic genes of immune cells, AA and NA 
differed regarding their expression of characteristic Th2 genes from HC (Table 15, Th2, LpA: 
p=0.05/0.03), with increased expression of Th2 genes in asthmatic subjects (data not shown). 
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Expression of Treg genes was significantly increased in AA compared to HC and NA without 
stimulation (Table 15, Treg, p=0.03/0.04). In PBMCs of NA, expression of characteristic 
macrophage genes was increased compared to HC and AA, without (Table 15, MP, 
p=0.006/0.05) and following LpA-stimulation (Table 15, MP, p=0.03/0.006). 
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Figure 26. TGF- signalling pathway in LpA-stimulated PBMCs of AA compared to HC. 
Ingenuity pathway of the KEGG gene selection for TGF- signalling; n(AA)=14, n(HC)=14. Color shading corresponds to the type of regulation: red for up-regulated genes, 
green for down-regulated genes. The shape of the node indicates the major function of the protein (see network shapes); a line denotes binding of the products of the two genes 
while a line with an arrow denotes 'acts on'. 
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Table 14: Characteristic genes of different immune cells 
 
 Cell type 
nTh Tfh NK Th1 Th2 Th9 
Gene Aff. ID Gene Aff. ID Gene Aff. ID Gene Aff. ID Gene Aff. ID Gene Aff. ID 
CD62L 7931914 CD200 8081657 KLRB1 7961059 STAT4 8057771 GATA3 7964360 PU.1 7947861 
CXCR4 7922219 TNFSF8 8163629 NKG2 7961187 TBX21 8008029 STAT6 7926105 IL9 8114256 
CCR7 8055465 CD40LG 8170187 IL4 8107977 Hlx 7909890 CCR3 8079383 IRF4 8116559 
IL2 8015031 CD44 7939341 IFNG 7964787 IRF1 8114010 CCR4 8078442 STAT6 7926105 
CD45RA 8102697 IL6R 7905789 NCR1 8031387 CXCR6 8079377 CCR8 8078888 GATA3 7964360 
  BTLA 8089519 NCR2 8119435 CD195 8093298 PTGDR2 7974363   
  PDCD1 8060294 NCR3 
8124955 
8178517 
8179773 
IL12RB1 8035380 IL4 8107977   
  ICOS 8047702 NLRK1 7961151 IL12RB2 7902205 IL5 8114023   
  IL21R 7994292 KLRC1 7961187 IL18R1 8044035 IL6 8131803   
  CD57 7952884 IL22 7964803 IFNG 7964787 IL13 8107970   
  CXCR5 7944335 IFNG 7964787 LTA 
8177976 
8118137 
8179258 
IL9 8114256   
  OX40 7911413 IL10 7923907 PRF1 7934161     
    IL21R 7994292 GNLY 8043236     
    IL1R1 8043995       
Cell type 
Th17 Th22 Treg B DC MP 
Gene Aff. ID Gene Aff. ID Gene Gene Gene Aff. ID Gene Aff. ID Gene Aff. ID 
RORC 7920082 AHR 8131614 FOXP3 FOXP3 CD19 7994487 HLA-DRA 8179481 CD14 8114612 
IL-23R 7902189 IL22 7964803 CD25 CD25 CD20 7940287 CD40 8063156 CD40 8063156 
CCR6 8123364 IL26 7964795 CTLA-4 CTLA-4 CD22 8027837 CD86 8082035 CD11b 7995096 
CCR4 8078442 IL13 8107970 GITR GITR CD40 8063156 CD83 8116983 EMR1 8025103 
KLRB1 7961059 CCR4 8078442 GARP GARP OCT2 8037123 CD11c 7995128 CD68 8004510 
IL23R 7902189 CCR6 8123364 CCR7 CCR7 Pax5 8161211 LAMP3 8092348 CSF1R 8115076 
IL17A 8120210 CCR10 8015681 CCR4 CCR4 CD79A 8029136 IFNA 8154627 IL4R 7994280 
IL17F 8127024 STAT3 8015607 TNFRSF9 TNFRSF9 BLK 8144625 MH±I 8115147   
IL21 8102707   TNFRSF4 TNFRSF4 POU2AF1 7951596 ICAM-1 8025601   
IL22 7964803   PDCD1 PDCD1   CD123 
8165752 
8176323 
  
IL26 7964795   RUNX1 RUNX1   CD64 7905047   
CCL20 8048864   IKZF2 IKZF2   CD32 7906757   
IL12RB2 7902205   ENTPD1 ENTPD1       
    GPR83 GPR83       
 
Aff. ID, Affymetrix gene ID; nTh, naïve T helper cell; 
Tfh, follicular T helper cell; NK, natural killer cell; 
Th1, T helper cell type 1; Th2, T helper cell type 2; 
Th9, T helper cell type 9; Th17, T helper cell type 17; 
Th22, T helper cell type 22; Treg, regulatory T cell; B, 
B cell; DC, dendritic cell; MP, macrophage (Raedler 
and Da Costa et al., manuscript in preparation). 
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Table 15: Regulation of KEGG pathways and characteristic genes of immune cells in 
                 PBMCs 
  
Analysis Nr. 
of 
genes 
  
PBMCs 
AA vs HC 
(14 vs 14) 
NA vs HC 
(8 vs 14) 
NA vs AA 
(8 vs 14) 
KEGG 
U CD3/28 LpA U CD3/28 LpA U CD3/28 LpA 
MAPK 282 0.085 0.471 0.011 0.111 0.226 0.055 0.102 0.096 0.028 
TGF- 91 0.108 0.312 0.000 0.017 0.214 0.115 0.225 0.395 0.051 
Apoptosis 88 0.035 0.169 0.015 0.142 0.212 0.129 0.097 0.195 0.239 
NK cyto 142 0.006 0.445 0.123 0.090 0.276 0.227 0.071 0.380 0.131 
Cyto-cyto 270 0.282 0.653 0.049 0.394 0.398 0.072 0.404 0.164 0.153 
p53 69 0.175 0.438 0.385 0.059 0.245 0.723 0.490 0.092 0.619 
TLR 102 0.149 0.286 0.024 0.181 0.251 0.015 0.057 0.043 0.040 
Comp 72 0.393 0.583 0.141 0.383 0.200 0.088 0.135 0.093 0.102 
TCR 111 0.015 0.196 0.042 0.079 0.156 0.065 0.141 0.673 0.061 
NOD 59 0.057 0.473 0.033 0.055 0.271 0.018 0.088 0.245 0.193 
Chemo 199 0.214 0.821 0.067 0.542 0.565 0.063 0.444 0.339 0.050 
Thyroid 68 0.325 0.247 0.407 0.526 0.622 0.906 0.457 0.930 0.724 
JAK 159 0.037 0.284 0.023 0.122 0.102 0.095 0.185 0.103 0.193 
Calcium 185 0.017 0.270 0.017 0.128 0.150 0.017 0.037 0.283 0.005 
mTOR 58 0.015 0.006 0.034 0.405 0.148 0.089 0.202 0.003 0.188 
Cell type 
 
U CD3/28 LpA U CD3/28 LpA U CD3/28 LpA 
nTh 5 0.079 0.586 0.092 0.689 0.738 0.303 0.267 0.223 0.844 
Tfh 12 0.430 0.549 0.290 0.576 0.293 0.162 0.733 0.232 0.176 
NK 14 0.527 0.366 0.337 0.149 0.563 0.187 0.183 0.619 0.487 
Th1 13 0.153 0.429 0.282 0.098 0.538 0.491 0.535 0.916 0.422 
Th2 11 0.244 0.492 0.047 0.310 0.162 0.026 0.339 0.108 0.728 
Th9 5 0.643 0.241 0.637 0.093 0.702 0.170 0.135 0.400 0.271 
Th17 13 0.156 0.634 0.425 0.088 0.163 0.515 0.148 0.069 0.547 
Th22 8 0.198 0.304 0.278 0.066 0.410 0.353 0.082 0.051 0.094 
Treg 14 0.034 0.273 0.099 0.428 0.319 0.507 0.036 0.857 0.798 
B 9 0.152 0.020 0.250 0.086 0.157 0.103 0.271 0.109 0.343 
DC 11 0.337 0.768 0.327 0.113 0.163 0.138 0.223 0.117 0.082 
MP 7 0.291 0.826 0.12 0.006 0.237 0.027 0.050 0.234 0.006 
 
KEGG, annotated pathways from the Kyoto Encyclopedia of Genes and Genomes. Cell type defined by 
characteristic genes for the respective cell subset. MAPK, mitogen-activated protein kinase signalling pathway; 
TGF-, transforming growth factor beta signalling pathway; NK cyto, natural killer cell mediated cytotoxicity; 
Cyto-cyto, cytokine-cytokine receptor interaction; TLR, toll-like receptor signalling pathway; Comp, complement 
and coagulation cascades; TCR, T cell receptor signalling pathway; NOD, NOD-like receptor signalling pathway; 
Chemo, chemokine signalling pathway; Thyroid, autoimmune thyroid disease; JAK, Jak-STAT signalling 
pathway; Calcium, calcium signalling pathway; mTOR, mTOR signalling pathway. p≤ 0.05 considered as 
significant; significant p-values presented in boldface. U, unstimulated. nTh, naïve T helper cell; Tfh, follicular T 
helper cell; NK, natural killer cell; Th1, T helper cell type 1; Th2, T helper cell type 2; Th9, T helper cell type 9; 
Th17, T helper cell type 17; Th22, T helper cell type 22; Treg, regulatory T cell; B, B cell; DC, dendritic cell; MP, 
macrophage (Raedler and Da Costa et al., manuscript in preparation). 
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We furthermore analysed a subpopulation of PBMCs, the CD4
+
 T lymphocytes, to study 
whethere genes and pathways within isolated CD4
+
 cells are more specific or sensitive 
compared to PBMCs. Due to limitations in cell numbers, this analysis was performed in a 
subgroup of 5 AA and 3 HC. In order to compare results for the isolated CD4
+ 
cells with 
PBMCs, we did a further analysis of PBMC data from the same subgroup of children (Table 
16, 5AA vs. 3HC).  
 
Table 16: Regulation of KEGG pathways and characteristic genes of immune cells in 
…………   PBMCs and CD4+ cells 
 
Analysis 
KEGG 
Nr. of 
genes 
PBMC s CD4+ 
AA vs. HC_unstimulated 
(14 vs 14) (5 vs 3) (5 vs 3) 
MAPK 282 0.085 0.0179 0.179 
TGF- 91 0.108 0.286 0.732 
Apoptosis 88 0.035 0.018 0.714 
NK cyto 142 0.006 0.019 0.732 
Cyto-cyto 270 0.282 0.732 0.732 
p53 69 0.175 0.732 0.732 
TLR 102 0.149 0.196 0.714 
Comp 72 0.393 0.732 1.000 
TCR 111 0.015 0.000 0.179 
NOD 59 0.057 0.714 0.714 
Chemo 199 0.214 0.732 0.732 
Thyroid 68 0.325 0.554 0.286 
JAK 159 0.037 0.000 0.196 
Calcium 185 0.017 0.018 0.732 
mTOR 58 0.015 0.018 0.196 
Cell type 
    
nTh 5 0.079 0.467 0.018 
Tfh 12 0.430 0.300 0.179 
NK 14 0.527 1.000 0.982 
Th1 13 0.153 0.400 0.714 
Th2 11 0.244 0.567 0.196 
Th9 5 0.643 0.333 0.982 
Th17 13 0.156 0.400 0.714 
Th22 8 0.198 0.167 0.196 
Treg 14 0.034 0.300 0.196 
B 9 0.152 0.000 1.000 
CD 11 0.337 0.267 0.732 
MP 7 0.291 0.333 0.714 
KEGG, annotated pathways from the Kyoto 
Encyclopedia of Genes and Genomes; cell type defined 
by characteristic genes for the respective cell subset; p≤ 
0.05 considered as significant; significant p-values 
presented in boldface. MAPK, mitogen-activated protein 
kinase signalling pathway; TGF-, transforming growth 
factor beta signalling pathway; NK cyto, natural killer 
cell mediated cytotoxicity; Cyto-cyto, cytokine-cytokine 
receptor interaction; TLR, toll-like receptor signalling 
pathway; Comp, complement and coagulation cascades; 
TCR, T cell receptor signalling pathway; NOD, NOD-
like receptor signalling pathway; Chemo, chemokine 
signalling pathway; Thyroid, autoimmune thyroid 
disease; JAK, Jak-STAT signalling pathway; Calcium, 
calcium signalling pathway; mTOR, mTOR signalling 
pathway. nTh, naïve T helper cell; Tfh, follicular T 
helper cell; NK, natural killer cell; Th1, T helper cell type 
1; Th2, T helper cell type 2; Th9, T helper cell type 9; 
Th17, T helper cell type 17; Th22, T helper cell type 22; 
Treg, regulatory T cell; B, B cell; DC, dendritic cell; MP, 
macrophage (Raedler and Da Costa et al., manuscript in 
preparation). 
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The results for the comparison of PBMCs from 14 AA with 14 HC are similar to the 
comparison of PBMCs from 5 AA to 3 HC. In the subgroup analysis, regulation of MAPK 
additionally reached significance (Table 16, MAPK, p=0.02). In the CD4
+
 cells, we could not 
observe significant differences in the regulation of KEGG pathways and characteristic genes of 
immune cells except for nTh (Table 16, nTh, p=0.02). Differences in the expression of Treg 
genes were no further significant in the PBMC subgroup, while B cell genes were significantly 
different expressed in the subgroup of 5 AA vs. 3 HC. 
 
In summary, we could identify TLR, calcium and mTOR signalling by GlobalAncova analysis 
to be significantly different regulated within PBMCs of the three phenotypes. 
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4. DISCUSSION 
 
The prevalence of atopic diseases in childhood increased dramatically over the past decades. In 
the results presented in this thesis, we investigated two different phases of immune maturation 
in the development of atopic disease: First, the early influence of genetic variation on immune 
regulation was studied in cord blood and children were followed until age 3 years to assess the 
development of atopic diseases. The aim was to study if the genotype of the fetus allows any 
prediction for immune maturation regarding atopy development later in life. Second, several 
dimensions of immune regulation were studied in children later in life, at the time of clinical 
manifestation of an allergic or non-allergic asthma phenotype, to identify currently unknown 
underlying immunological mechanisms. 
 
Immune regulation in early childhood 
Exogenous influences such as gene-environment interactions and their impact on immune 
regulation become more and more important for the development of atopic diseases in 
childhood. Genetic predisposition is considered as one key risk factor for development of 
atopic diseases (Moffatt et al. 2007), and several published reports have shown an association 
between the presence of certain genetic variants of Toll-like receptors or specific Interleukin-
10 genotypes and development of atopic diseases in both children and adults. In the 
experiments presented herein, we studied the impact of certain TLR and IL-10 SNPs on various 
aspects of the immune response in a German birth cohort at the University Children’s Hospital 
in Munich, Germany. Importantly, as opposed to numerous other published studies employing 
patient populations of childhood and adult age, we obtained and analysed cord blood, therefore 
allowing us to perform our studies at the earliest possible time point of immune maturation. 
Furthermore, we were able to follow these children to precisely assess atopic phenotypes and 
wheeze until the age of 3years. 
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Among the TLR polymorphisms that were studied, genetic variants of TLR2 were shown to 
influence Treg marker gene expression, with expression levels being modulated by maternal 
atopy. In carriers of IL-10 SNPs within the same study population, we observed a distinct 
pattern of T cell lineage fate, with decreased expression of Treg markers, decreased levels of 
TNF- GM-CSF and IL-5 and a concomitant increase in IFN- levels. Genetic variants of 
TLRs and IL-10 were shown to act as determinants for the development of immune-mediated 
diseases including atopic dermatitis and wheeze in early childhood at 3 years of age. 
In the second part of this work, we addressed immune regulation later in childhood, studying 
the underlying immunoregulatory and pathophysiological mechanisms of the two main 
phenotypes in childhood asthma, allergic and non-allergic asthma, at the onset of disease. 
While both allergic and non-allergic asthmatic children shared a Th2 dominated phenotype, 
they clearly differed in specific immunological aspects. Our experiments showed an increase in 
total numbers of Tregs in children with asthma of allergic origin compared to non-allergic 
asthmatics and healthy controls. This increase might be explained as a physiological response 
in order to balance exuberant immune responses and to compensate for the decreased 
suppressive capacity of Tregs in patients with allergic asthma. This might enable the child to 
more efficiently control the ongoing inflammatory response. Although, the decrease in 
suppressive capacity of Tregs from AA compared to HC did not reach statistical significance, 
mild differences in suppressive capacity together with changes in cytokine secretion may have 
a biological impact. 
In contrast, patients with asthma of non-allergic origin were found to have increased levels of 
the pro-inflammatory cytokine IL-1 and showed a shift towards a Th17 phenotype with 
elevated numbers of neutrophils in peripheral blood.  
Employing a genome-wide microarray expression analysis, we were able to characterize 
childhood allergic and non-allergic asthma based on a newly described specific gene 
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expression profile, including CD93, TREM1 and S100A9 which were significantly increased in 
non-allergic asthmatic compared to allergic asthmatic children and also healthy controls. 
 
The prevalence of atopic diseases in childhood increased dramatically over the past decades, 
especially in countries with a westernized lifestyle and high hygiene standards (Matricardi et 
al. 2000). The so-called “hygiene hypothesis” proposes that a lack of early childhood exposure 
to various antigens (infectious agents, microorganisms, parasites among others) increases 
susceptibility to atopic disease by suppressing natural development of the immune system. This 
process is in part mediated by TLRs, a family of conserved innate immune receptors that 
recognize pathogen-associated molecular patterns of microbes (Raedler and Schaub, 2013). 
Published work suggests that genetic polymorphisms and associated gene-environment 
interactions play a prominent role in disease development (Le Souef P.N., 2009; Niebuhr et al. 
2008; Pinto et al. 2008; Vercelli D., 2008). 
In the experiments shown herein, the TLR2 SNPs rs4696480 and rs1898830 influenced Treg 
marker gene expression, a finding supported by recent reports suggesting a direct or indirect 
modulation of Tregs by TLRs (Dai et al. 2009; Liu et al. 2006; Nyirenda et al. 2009).  
Of note, the two above mentioned TLR2 SNPs showed a diametrical effect on Treg marker 
expression, which was dependent on maternal atopy. This might point to an 
immunomodulatory effect caused by the presence or absence of maternal atopy, which could 
already have an impact on neonatal immune maturation. However, the underlying mechanisms 
are incompletely understood. Direct intrauterine immunological pathways, epigenetic 
regulation or currently unknown genetic and immune-mediated modulation have been 
suggested (Liu and Raedler et al. 2011). Since we did not detect an accumulation of the TLR2 
risk alleles in atopic mothers, an influence of maternal genotypes on Treg modulation of the 
fetus is unlikely. 
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In children with TLR2 SNP rs4696480 (AA), Tregs at birth were found to be decreased in the 
absence of maternal atopy. In contrast, children with the same SNP, but whose mothers were 
known to have atopic disease, had elevated numbers of Tregs and showed a shift towards a Th2 
phenotype with predominance of the Th2 cytokines IL-5 and IL-13 and the pro-inflammatory 
cytokine TNF-. Physiological up-regulation of Treg numbers during early childhood might 
potentially counterbalance a present Th1/Th2 disparity in this subgroup, and has been 
implicated with manifestation of atopic disease in childhood (Van der Velden et al. 2001). In 
another study published by Eder et al., carriers of the WT allele (T) of TLR2 rs4696480 among 
a population of farmers´ children were shown to have a lower risk to develop atopic diseases 
(Eder et al. 2004). In a study published by Kormann et al. (Kormann et al. 2008), carriers of 
TLR2 SNP rs1898830 showed a trend towards developing non-atopic asthma, although this 
correlation was not found to be significant. In our study, carriers of the TLR2 SNP rs1898830 
(GG) who had atopic mothers, were found to have lower expression levels of Treg markers, 
indirectly indicating that those patients are likely to have lower total Treg numbers. Of note, 
Treg markers such as FOXP3 had to be used as an indirect mean to estimate total number of 
Tregs, since counting total cells by flow cytometry was not feasible due to a limited amount of 
cells available from each patient for this assessment. A decrease of FOXP3 expression could 
indicate lower numbers of total Tregs and as a consequence potentially less 
immunosuppression. Consistent with this hypothesis is a report by Lazarus et al., showing an 
association between decreased FOXP3 levels in children with the TLR10 SNP rs4129009 and 
clinically diagnosed asthma (Lazarus et al. 2004). In our study, following non-specific innate 
stimulation with LpA and Ppg, we also observed decreased FOXP3 expression in homozygous 
carriers of both, the TLR10 SNP rs4129009 and the TLR1 SNP rs4833095, yet we did not 
observe an association with risk for atopic disease or wheeze at the age of 3 years. The ligand 
spectrum of TLR10 might actually be more complex due to a possible heterodimerization of 
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TLR1 with TLR2, and the fact that TLR10 is highly homologous to TLR1 and TLR6, which 
are both able to form heterodimers with TLR2 (Liu and Raedler et al. 2011; Takeuchi et al. 
2002). 
 If both TLR2 SNPs (rs4696480 and rs1898830) were stratified for maternal atopy, clinical 
outcomes assessed at the age of 3 years might be explained by cord blood immune responses. 
Consistent with this finding, increased expression of Treg markers at birth generally correlated 
with protection against wheeze (rs1898830) and atopy (rs1898830, rs4696480), whereas 
decreased expression of Treg markers was associated with increased risk for developing food 
allergy (rs4696480). 
Together the data indicate that a certain TLR genotype in combination with presence or absence 
of maternal atopy allow a further prediction for immune maturation regarding development or 
protection against atopic diseases in early childhood.  
It has to be acknowledged that these findings have to be verified in the next follow-up of this 
study population at the age of 6 years, where additional atopic phenotypes such as asthma can 
be objectively assessed, and as well in additional cohort studies employing cord blood T cells, 
as only this can predict later effects during immune maturation (Liu and Raedler et al. 2011). 
 
 
In addition, we studied the impact of genetic variation in the IL-10 gene on Th1/Th2 lineage 
and pro-inflammatory cytokines as well as Treg marker genes in cord blood. IL-10 is known to 
be a key mediator of adaptive immunity. Due to its pleiotrophic effects and its role in 
regulation of both cellular and humoral immunity, it became a candidate risk gene in the 
regulation of various inflammatory and autoimmune diseases (Lyon et al. 2004). Several IL-10 
SNPs were previously associated with inflammatory disorders, such as asthma (Bossé et al. 
2009; Hunninghake et al. 2008; Chatterjee et al. 2005), lupus erythematosus (Gibson et al. 
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2001), psoriasis (Asadullah et al. 2001), rheumatoid arthritis (Paradowska-Gorycka et al. 2010) 
and certain infectious diseases (Shin et al. 2000).  All of these conditions are likely to be at 
least in part T cell-mediated and are considered to have their clinical onset during early 
immune maturation. We observed a distinct pattern of T cell linage fate in cord blood of IL-10 
SNP carriers, with decreased gene expression of Treg markers, decreased levels of TNF- 
GM-CSF and IL-5, and a concomitant increase in IFN- levels. The observed decrease in Treg 
marker gene expression could indicate lower numbers of Tregs, what has been described for 
children with wheeze at the age of 8-20 months (Borrego et al. 2009). 
Despite the fact that IL-10 was originally discovered as  “cytokine synthesis inhibitory factor” 
capable of suppressing the Th1 response in a study by Fiorentino and colleagues, within our 
study, IFN- secretion was increased in homozygous carriers of IL-10 SNPs (Fiorentino et al. 
1991). Of note, the results have to be evaluated carefully, considering the fact that in this study, 
cytokine levels were assessed in bulk culture supernatants. As a consequence the origin of IFN-
 cannot be attributed exclusively to Th1 cells. The finding that IL-5, TNF- and GM-CSF 
were decreased in homozygous carriers of IL-10 SNPs rather indicates an atopy-protective state 
of immune development (Raedler et al. 2012). Despite this observed shift from a Th2 towards 
a Th1 phenotype and reduced pro-inflammatory cytokines, several IL-10 SNPs were found to 
be risk factors for AD, wheeze or both in the follow-up at 3 years of age.  
In the past, contradictory results regarding IL-10 SNPs and their association with atopy or 
asthma have been reported. This can probably be attributed to differences in study design, 
different assessment of the clinical phenotype or failure to adequately model gene-environment 
interactions among others (Hunninghake et al. 2008; Raedler et al. 1012). The minor allele of 
rs3024498 proofed to be a risk factor for AD and wheeze in our study population as well as a 
risk factor for childhood asthma in the study population of the Canadian Asthma Primary 
Prevention Study (CAPPS; Bossé et al. 2009). In contrast, presence of the same allele was not 
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associated with increased risk for developing asthma in the Canadian Saguenay-Lac-Saint-Jean 
(SLSJ) study population or in a German asthma family study (Bossé et al. 2009). In children 
representing the Study of Asthma Genes and the Environment cohort, presence of the minor 
allele of rs3024498 even seemed to protect from development of atopic disease (Bossé et al. 
2009). Regarding the IL-10 SNP rs1800871 we did not observe an association with a disease 
outcome, whereas the same SNP was associated with adult asthma in the Canadian SLSJ study 
population (Bossé et al. 2009). Homozygous carriers of the IL-10 SNP rs3024496 showed a 
higher prevalence of AD, wheeze or both within our study population, a finding that is 
consistent with a study from Hunninghake and colleagues, showing augmented levels of IgE 
and increased risk for development of asthma at high levels of dust mite exposure in the 
Childhood Asthma Management Program study population (Hunninghake et al. 2008). 
 Interestingly, within our study, IL-10 SNPs affected both AD and wheeze, two potentially 
distinct diseases. 
While six single IL-10 SNPs were associated with clinical outcomes at 3 years of age, we did 
not detect a high-risk haplotype, containing all six minor alleles. This might be explained by 
the fact that the number of heterozygous SNP carriers was higher, the majority of which 
showed a lower prevalence of AD and wheeze compared to homozygous SNP carriers.  
Using diplotype analysis, the IL-10 SNP rs3024498 and/or the deletion rs79309463 could be 
shown to be involved in the development of wheeze, whereas the distal promoter SNPs 
rs10494879 and/or rs1800890 might play a role in the development of AD in childhood. The 
effect of these two SNP/SNP or SNP/deletion combinations could not be disentangled, as these 
two homozygous SNP/deletion genotype combinations alone did not occur within this study 
population (Raedler et al. 2012). 
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Hee and colleagues proposed IL-10 to be controlled at transcriptional level. The authors 
suggested IL-10 SNPs to affect the binding of regulatory sequences to the IL-10 promoter, 
therefore resulting in changes in IL-10 production (Hee et al. 2007). In our study population 
we did not observe an influence of the IL-10 genotype on IL-10 mRNA or protein levels. 
Supporting our findings, Hayden et al. did not observe an association between IL-10 promoter 
SNPs and IL-10 levels in Derp1-stimulated PBMCs of children (Hayden et al. 2011). Also 
consistent with our findings, they did however describe an association of the IL-10 SNPs with 
Th2 cytokine levels, indicating a crucial role for IL-10 in Th2 cytokine regulation (Hayden et 
al. 2011; Raedler et al. 2012). Since the effects of IL-10 SNPs were not mediated by changes 
in IL-10 levels, a modulation in binding of the transcription factor AP-1 (activator protein 1), 
which influences IL-10 promoter activation as well as Treg regulation would be possible (Kube 
et al. 1995; Wu et al. 2006; Raedler et al. 2012). However, the exact mechanism still has to be 
determined. 
In summary, polymorphisms in IL-10 seem to favour an atopy-prone immune development and 
to affect early immune maturation prior to onset of clinical disease, whereas Tregs might play a 
more fundamental role at this stage of immune development compared to Th1/Th2 cytokine 
lineages (Raedler et al. 2012).  
Our results show that both TLR and IL-10 polymorphisms influence immune regulation in cord 
blood and act as determinants for development of atopic diseases or wheeze later in life.  
Based on these findings, in ongoing studies we are currently analyzing the role of the 
polymorphisms in TLRs, IL-10 and additional candidate genes (identified e.g. within GWAS in 
asthma) in the development of allergic and non-allergic asthma later in childhood (Moffat et al. 
2007; Moffat et al. 2010). 
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Immune regulation at school-age 
In a second set of experiments, we investigated the mechanisms of immune regulation in 
asthmatic children at the onset of disease. From a clinical perspective, there are two main 
phenotypes of childhood asthma: allergic and non-allergic asthma. Despite intensive research 
over the past decades, the underlying pathophysiological mechanisms remain incompletely 
understood. Importantly, current treatment protocols for asthmatic children follow a “one-size-
fits-all approach” including the administration of a short-term -agonist and an inhalative 
corticosteroid, and therefore do not take potential phenotypic differences into account. 
 
Employing very strict inclusion criteria, we were able to recruit a unique study population 
including AA, NA and healthy children. Since asthmatic children were recruited at the first 
visit to the asthma and allergy outpatient clinic of the children´s hospital in Munich, we were 
able to include the children at disease onset or early after disease development, a timepoint at 
which they were still in a steroid-naïve state. After retrieving a detailed patient history, patients 
underwent physical examination and blood testing for specific immunological markers. In 
order to reliably distinguish between the allergic and non-allergic phenotype of asthmatic 
disease, data on specific and total immunoglobulins, fractional exhaled nitric oxide (FeNO) as 
a measure of airway inflammation and radioimmunoassays for detection of specific IgE 
antibodies were all taken into account. With the allergic phenotype being more common than 
the non-allergic type and representing about 90-95% of the total number of asthmatic cases in 
children (Craig et al. 2010), this unequal distribution of both phenotypes was also reflected in 
our patient population, with the frequency of AA being five times higher than that of NA.  
 
Our results imply that AA and NA can be characterized by distict immunological profiles 
(Raedler et al., manuscript in preparation). Patients with AA had higher levels of Tregs 
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compared to patients with NA and HC, as comprehensively assessed by flow cytometric 
measurement, gene expression analysis by qRT-PCR and microarrays and epigenetic analysis 
of FOXP3 TSDR. In order to quantify Tregs by flow cytometry, we measured the transcription 
factor FOXP3, which currently represents the most specific marker for Tregs, and added 
CD49d as an additional surface marker. CD49d has previously been reported to be absent on 
immunosuppressive Tregs by Kleinewietfeld and colleagues (Kleinewietfeld et al. 2010). Since 
the total number of CD4
+
CD25
+
CD49d
-
 cells was shown to correlate well with the total 
number of CD4
+
CD25
+
FOXP3
+
 cells, the use of anti-CD49d (which binds to an integrin alpha 
subunit) could facilitate the isolation of “untouched” suppressive regulatory T cells by negative 
selection as suggested by Kleinewietfeld et al. In accordance to our flow cytometry data, 
microarray experiments revealed increased Treg gene expression in AA compared to NA and 
HC. 
To distinguish between natural, thymus-derived and induced Tregs, which are induced in the 
periphery, we analysed the methylation status of the Treg-specific demethylated region 
(TSDR). Demethylation in this region was suggested to be characteristic for nTregs in adults, 
whereas this region is methylated in effector cells and induced Tregs (Baron et al. 2007). As 
the demethylation status of TSDR did not differ between unstimulated and anti-CD3/CD28-
stimulated cells, we could demonstrate that TSDR demethylation is a specific marker to 
quantify nTregs, but not stimulated iTregs, in PBMCs of children. Treg numbers assessed by 
TSDR demethylation analyses were trendwise increased in AA compared to HC, in accordance 
to our data from flow cytometric measurements, microarray and qRT-gene expression 
analyses. 
To study the role of epigenetic regulation on the expression of FOXP3, we assessed the 
acetylation status of the histone proteins H3 and H4. Acetylation of histones alters the 
chromatin condensation and thereby increases the accessibility of transcription factors that 
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thereafter regulate gene expression (Struhl K., 1998). Zhang et al. suggested that FOXP3 
expression and protein activity are controlled by acetylation of FOXP3 (Zhang et al. 2012). 
While acetylation did not differ at H4 within our study population, acetylation was trendwise 
higher at histone H3 and might be associated with increased FOXP3 mRNA and protein levels 
in AA. Consistent with our data, Cavassani et al. demonstrated an association of acetylation at 
histone H3, but not H4, with FOXP3 expression (Cavassani et al. 2010). 
 
While the total number of Tregs was increased in children with allergic asthma, their relative 
suppressive capacity, especially for Th2/Th1 cytokine secretion, was found to be decreased.  
In previous cord blood studies from our group, we could show a decrease in Treg numbers in 
children at risk for asthma (Schaub et al. 2008), while Treg numbers were increased in children 
protected from asthma (Schaub et al. 2009). Interestingly, the effects were different in cord 
blood and in peripheral blood of children at school age. While children at risk for asthma had 
decreased Treg numbers in cord blood, Treg numbers were increased in peripheral blood of 
asthmatic children within our study. In a 2012 review by Langier et al., Tregs were reported to 
be altered in number and function in allergic asthmatics; however the results in the literature 
vary between children and adults and blood cells and airway tissue (Langier et al. 2012). 
Lower numbers of CD4
+
CD25
+
 cells were found in blood and BAL of asthmatic children 
compared to HC (Lee et al. 2007; Hartl et al. 2007).  Of note, measurement of CD4
+
CD25
+
 
cells (without analysis of intracellular FOXP3 levels) does not allow to reliably characterize 
regulatory T cells. In PBMCs of allergic children with persistent moderate to severe asthma, 
CD4
+
CD25
+
FOXP3
+
 cells and IL-10 mRNA levels were increased compared to mild 
asthmatics, and Treg numbers showed a positive correlation with total IgE levels (Lee et al. 
2007). Thunberg et al. observed an increase in Treg numbers in mild asthmatics following 
allergen inhalation, suggesting an association of number of Tregs with the clinical degree of 
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airway inflammation in asthma (Thunberg et al. 2010). Consistent with reports from Thunberg 
et al., our data suggest a counter-regulatory process in children with AA, during which total 
numbers of Tregs increase in order to compensate for their reduced relative functional capacity. 
Consistent with our suppression data, yet not significant, Yamamoto et al. also described an 
impaired suppressive capability of Tregs in asthmatic children (Yamamoto et al. 2011). 
Regarding the underlying pathophysiological mechanism of suppression excerted by Treg 
cells, Yamaguchi et al. suggested two main categories of suppression, depending on the degree 
of inflammation present. Under physiological, non-inflammatory conditions, the authors 
suggest a Treg-dependent deprivation of activation signals, including the inhibition of CD28 
co-stimulatory signals, CTLA-4 dependent down-regulation of CD80/CD86, IL-2 absorption 
and CD39/CD73-dependent ATP-degradation, in order to keep the responder cells in a naïve 
state. In contrast, in the presence of severe inflammation, conventional T cells are suppressed 
via an inactivating mechanism, including secretion of IL-10, TGF-, IL-35, granzyme, perforin 
and cAMP (Yamaguchi et al. 2011). First results of our study concerning the molecular 
mechanism of Treg suppression indicate reduced suppression of Th2 responses in AA 
compared to HC. In our ongoing studies, we are currently studying the molecules that were 
previously suggested by others to contribute to the suppressive mechanism on mRNA level in 
isolated Tregs. 
In summary, Treg numbers assessed by flow cytometry, mRNA levels of Treg marker genes 
determined via microarray and qRT-PCR and epigenetic analysis of FOXP3 acetylation and 
methylation at the Treg-specific demethylated region, indicate increased numbers of Tregs in 
AA compared to HC and NA, while suppressive capacity was decreased in AA compared to 
HC.  
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In contrast to patients with AA, NA were characterized by significantly increased levels of the 
pro-inflammatory cytokine IL-1, a finding that was observed both at gene and protein level. A 
possible role of IL-1 in asthma pathology has already been implicated in a report from 1994, 
in which intratracheal administration of IL-1 in rats was associated with AHR and increased 
neutrophil counts in BAL (Tsukagoshi et al. 1994). In a different study, IL-1 levels were 
found to be increased in bronchial epithelium from asthmatic patients compared to healthy 
controls. Epithelial IL-1 expression was positively correlated with the number of subepithelial 
macrophages, indicating a possible association between IL-1 expression and the degree of 
ongoing inflammation in bronchial asthma (Sousa et al. 1996).  
Consistent with previous reports by Tsukagoshi and colleagues employing a mouse model, we 
measured elevated IL-1ß as well as increased neutrophil counts in whole blood of NA within 
our study population. In a study from 2000, NA had already been shown to have increased 
numbers of neutrophils compared to AA and HC; however these investigators analysed tissue 
obtained from bronchial biopsies (Amin et al. 2000), as opposed to peripheral blood in our 
study.  
In addition to elevated levels of the pro-inflammatory cytokine IL-1, we detected an up-
regulation of IL-37 gene expression in NA. IL-37, which is a member of the IL-1 cytokine 
family, has anti-inflammatory properties and has been shown to suppress innate immune 
responses (Nold et al. 2010). Furthermore a role in suppression of adaptive immunity has been 
proposed previously (Kim and Kroneberg, 2011). IL-37 was shown to directly inhibit 
expression, production and function of pro-inflammatory cytokines and the chemokine 
CXCL2, a neutrophil chemoattractant (Tete et al. 2012; Kim and Kroneberg, 2011). 
Considering our current results, we suggest that IL-37 gene expression is physiologically up-
regulated in patients with NA, in order to counteract the IL-1-driven, predominantly 
neutrophilic inflammation. Consistent with this hypothesis is the finding by others, that IL-37 
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undergoes extensive posttranscriptional regulation. IL-37 might be part of a feedback 
mechanism during termination of the inflammatory response, since stability of IL-37 mRNA 
and expression levels of IL-37 have been shown to depend on the presence of inflammatory 
stimuli (Kim and Kroneberg, 2011). 
Studying cytokine profiles, we observe a Th17-shifted profile in NA compared to AA and HC. 
Th17 cells are involved in activation and proliferation of neutrophils and were therefore 
proposed to play a prominent role in the pathogenesis of asthma; non-allergic asthma in 
specific, since it was associated with a neutrophil-driven airway inflammation (Louten et al. 
2009; Molet et al. 2001; Laan et al. 1999). In addition to the measurement of single Th1, Th2, 
Th17 and pro-inflammatory cytokines, we also assessed the ratios between the different 
cytokines, which has previously been suggested by Wong et al. in order to better reflect 
cytokine homeostasis (Wong et al. 2001; Colavita et al. 2000).  In our experiments NA had 
higher ratios of Th17/Th1, Th17/Th2 and Th17/pro-inflammatory cytokine producing cells 
than AA or HC. We believe that using cytokine ratios, as opposed to comparison of single 
cytokines, provides a better reflection of cytokine balance present in the individual patient in a 
more physiological context. Studying cytokine ratios in our experiments revealed a clear Th17 
predominance in NA compared to AA and HC. 
Employing microarrays followed by validation of the results by qRT-PCR, we could identify 
three genes (CD93, S100A9 and TREM1), which were significantly higher expressed in NA 
compared to HC and AA. CD93 has a role in several cellular regulation processes, including 
tissue repair and might therefore be important during tissue remodelling in patients with 
asthma. The pro-inflammatory molecule S100A9 has already been shown to be up-regulated 
during the early airway response in several animal models of atopic diseases. In addition to its 
function as a mediator of inflammation in autoimmunity, S100A9 also seems to be involved in 
the pathogenesis of other diseases in which inflammation has a prominent pathophysiological 
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role, including Crohn´s disease or rheumatoid arthritis (Yin et al. 2008; Simard et al. 2010). 
Both CD93 and S100A9 are calcium binding molecules and might therefore be involved in the 
regulation of calcium signalling. Of note, in our study population regulation of calcium 
signalling differed significantly among the three groups (AA, NA and HC). A dysregulation of 
calcium responses has been associated with pathophysiological processes of autoimmune and 
inflammatory diseases (Feske et al. 2007), yet a possible role for calcium signalling, including 
the underlying molecular mechanisms, in the development of childhood asthma remains 
controversial, and is subject of ongoing studies within our study population. 
TREM1 has previously been shown to be a mediator of the neutrophil-driven inflammatory 
response (Schenk et al. 2007). This finding is consistent with the Th17-shifted neutrophilic 
inflammation that we observed in NA. TREM-1 has previously been shown to play a crucial 
role during the acute inflammatory response following certain forms of bacterial infection and 
has also been shown to co-localize with TLR4 upon stimulation of human neutrophils (Fortin 
et al. 2007). Consistent with these reports is our finding, that the expression of TLRs, including 
TLR4, was increased in NA compared to AA and HC. TLRs are considered as key players in 
immunity and serve as mediators of both innate and adaptive immune responses. Genetic 
variants of TLRs have been shown to have an impact on the development of various immune-
mediated diseases, including asthma, AD and wheeze, as shown in our current work (Schwartz 
and Cook, 2005; Liu, Raedler et al. 2011).  
The afore-presented data imply that the pathophysiology of non-allergic asthmatics is 
characterized by a Th17-shifted neutrophilic inflammation with significantly increased levels 
of pro-inflammatory IL-1. Furthermore, expression of the two calcium binding molecules 
CD93 and S100A9 was significantly increased in NA compared to AA and HC and could 
therefore serve as biomarkers to immunologically distinguish between asthmatics of allergic 
and non-allergic origin. As transcriptional regulation of the calcium signalling differed 
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significantly within the three phenotypes, we hypothesize a possible role for calcium signalling 
and its underlying molecular mechanisms in asthma pathogenesis. 
 
There is increasing evidence that, besides the Th1/Th2 paradigm, additional cell types are 
involved in the pathogenesis of asthma. Nevertheless, dysregulation of Th1 and Th2 cells is 
still considered to play a major role in asthma (Colavita et al. 2000). Since a maladapted Th2 
response was reported to be the crucial factor in the pathophysiology of allergic asthma (Kiley 
et al. 2007; Bosnjak et al. 2011), we measured cytokine levels of the characteristic Th2 
cytokines IL-5 and IL-13 in cell supernatants of our study population. Th2 cytokine levels were 
increased in asthmatics, both AA and NA, compared to HC. Particularly IL-5 was significantly 
elevated in AA and NA compared to HC and secretion was even more elevated in NA 
following adaptive stimulation, although the latter finding was not statistically significant. 
Consistent with these findings, our microarray experiments revealed significant differences in 
Th2 regulation between AA or NA compared to HC, with higher Th2 gene expression in 
asthmatics, further indicating a common Th2-biased immune phenotype in both allergic and 
non-allergic asthmatic children. 
Levels of the classical Th1 cytokine IFN- were decreased in cell supernatants of asthmatics 
compared to HC. This decrease has already been reported in PBMCs of moderate atopic 
asthmatic children by Hoekstra and colleagues (Hoekstra et al. 1997). Within our study 
population, levels of IFN- were similar between AA and NA, with a tendency towards lower 
levels in the non-allergic phenotype, compared to the allergic phenotype.  
Since epigenetic regulation is considered an important factor during effector T cell 
development and epigenetic changes in CD4
+
 T cells have been associated with autoimmune 
diseases (Perl A., 2010), we determined levels of DNA methylation within the IFN- promoter 
region, as well as histone H3 and H4 acetylation in CD4
+
 cells. While OVA 
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sensitization/challenge led to an increase in IFN- promoter methylation in CD4+ cells in a 
mouse model (Brand et al. 2012), we did not detect any differences in methylation status 
within the human IFN- promoter region. Furthermore, IFN- acetylation at the histone 
proteins H3 and H4 did not differ in HC and AA, which is contradictory to findings in mouse 
models, in which the protective effect of Acinetobacter lwoffii F78 was at least in part 
mediated via protection against the loss of H4 acetylation (Brand et al. 2011). 
 
T helper cells, as component of the adaptive immune system and moreover cells of the innate 
immune system are regulated by TGF-, which suppresses immune responses by inhibiting the 
function of inflammatory cells and by promoting the suppressive capacity of Treg cells (Wan 
Y.Y., 2008). TGF- was reported to play a major role in asthma, especially in airway 
remodelling, a process associated with decreased pulmonary function of asthmatics (Makinde 
et al. 2007). While elevated levels of TGF- have been observed in asthmatic airways, 
especially in severe asthmatics (Makinde et al. 2007), expression of characteristic genes of the 
TGF- signalling pathway, including Smad2/3 and TGF- itself, were decreased in both 
childhood asthma phenotypes compared to HC within our study population, and Smad6 and 
Smad7, two negative regulators of TGF- signalling, were up-regulated in AA compared to HC 
(Makinde et al. 2007), however microarray expression results still have to be validated by 
qRT-PCR. 
In contrast, increased TGF- signalling and Smad2/3 expression have been shown in asthmatic 
airways (Bossé and Rola-Pleszczynski, 2007; Torrego et al. 2007). These different findings 
might be explained by the different biological material which was investigated and Bossé and 
Rola-Pleszczynski suggest that TGF- activity is not directly related to gene expression, but 
might be increased at other points of control (Bossé and Rola-Pleszczynski, 2007). As a 
measure of transcriptional activity, Sagara et al. determined the phosphorylation status of 
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Smad2 and could thereby show increased TGF- signalling in asthmatics and an association 
with airway remodelling in asthma (Sagara et al. 2002). To determine the amount of 
phosphorylated Smad2 and Smad3, which translocate to the nucleus and are directly involved 
in regulation of TGF--dependent gene expression, would be necessary to clarify the role of 
TGF- signalling within allergic and non-allergic children within our study population.  
 
In summary, AA and NA together share a Th2-biased phenotype, while Th1 cells are reduced 
in numbers in both phenotypes. The lower levels of IFN- in AA compared to HC could not be 
attributed to epigenetic regulation via IFN- promoter methylation or histone H3 or H4 
acetylation. Neither the measurement of Th1 nor Th2 cytokine levels allowed a discrimination 
between allergic and non-allergic asthmatic children. 
 
Due to the complexity of the asthma phenotypes, we decided to additionally investigate CD4
+
 
cells by microarrays, which were suggested to play a major role in asthma pathogenesis 
(Robinson et al. 2010). The isolated CD4
+
 cells from the subgroup of AA and HC solely 
differed in nTh gene expression but not within any KEGG pathways. These results indicate that 
the regulation of asthma seems to be more complex and not mainly mediated by a 
dysregulation of CD4
+ 
cells but potentially an interplay between several cell types from the 
PBMC population, including CD4
+
, CD8
+
, B and natural killer cells, basophils and dendritic 
cells.  
By assessing several dimensions of immune regulation, we have shown that the underlying 
pathophysiological mechanisms of allergic and non-allergic asthma share some degree of 
homology but differ in cytokine profiles as well as T cell regulation. 
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5. SUMMARY 
 
The prevalence of atopic diseases in childhood increased dramatically over the past decades, 
especially in industrialized countries. However, little is known about the underlying 
mechanisms of immune regulation during infancy and at the onset of atopic diseases.  
In my thesis, I have studied the regulation of different T cell subpopulations and the impact of 
genetic predisposition and epigenetic regulation on the development of atopic diseases at two 
different time points: early in life (cord blood) and later in childhood (age 4-15 years). 
In contrast to numerous other published studies examining atopic diseases in children and 
adults, we assessed immune regulation in cord blood, therefore allowing us to perform our 
studies at the earliest possible time point of immune maturation. In addition, we assessed 
immune responses later in childhood during manifestation of disease, which offered the unique 
opportunity to identify important regulatory pathways that are key determinants for the 
development of childhood asthma. 
 
In my experiments I obtained the following results: 
1) Among the innate TLR polymorphisms addressed in our birth cohort study, genetic variants 
of TLR2 were shown to impact T regulatory cell (Treg) marker gene expression in cord 
blood, with expression levels being modulated by maternal atopy.  
In carriers of IL-10 SNPs within the same study population, we observed a distinct pattern 
of cord blood T cell lineage fate, with decreased expression of Treg markers, decreased 
levels of pro-inflammatory TNF- GM-CSF and IL-5 (Th2 cytokine), and a concomitant 
increase in IFN- (Th1 cytokine) levels. Importantly, genetic variants of TLRs and IL-10 
were shown to be determinants for the development of atopic diseases in early childhood 
until 3 years of age. 
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2) The two main clinical phenotypes of childhood asthma (allergic and non-allergic asthma) 
differed regarding their underlying pathophysiological mechanisms when studied during 
manifestation of disease in childhood: Children with allergic compared to non-allergic 
asthma and healthy children, were found to have increased total numbers of regulatory T 
cells (Tregs) in parallel with reduced suppressive capacity of Tregs.  
The increase in total numbers of natural, thymus-derived Tregs (nTregs) could additionally 
be confirmed by epigenetic regulation of the Treg-specific demethylated region (TSDR), 
with higher demethylation found in allergic asthmatics. 
The increase in Tregs could represent a physiological response to the ongoing allergic 
inflammation found in allergic asthmatics, in order to compensate for the pathologically 
enhanced inflammatory reaction. Of note, the children develop the allergic asthmatic 
phenotype despite increased numbers of Tregs, indicating that this control mechanism is 
still not sufficient, possibly explained by a reduced suppressive capacity of Tregs.  
Importantly, our study showed that children with asthma of non-allergic origin have 
increased levels of the pro-inflammatory cytokine IL-1, increased IL-37 expression and a 
Th17-shifted immune phenotype with elevated numbers of neutrophils in peripheral blood, 
compared to allergic asthmatics and healthy controls. 
Thus, the non-allergic phenotype was immunologically quite distinct from the allergic 
asthmatic phenotype, characterized by a Treg-dominated immune response, and showed a 
Th17-shifted pro-inflammatory immune milieu promoting neutrophilic inflammation. 
Interestingly, in our study both allergic and non-allergic asthmatic children shared a Th2-
dominated phenotype. 
3) Employing genome-wide microarray expression analysis, which was confirmed by qRT-
PCR, we identified novel specific gene expression profiles for childhood allergic and non-
allergic asthma. We observed increased expression of the two calcium binding molecules 
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CD93 and S100A9 and of TREM1, associated with neutrophilic inflammation, in PBMCs of 
non-allergic asthmatics compared to allergic asthmatics and healthy children. Additionally, 
both asthma phenotypes differed significantly regarding their expression of genes of the 
TLR, calcium and mTOR signalling pathways. 
 
Together our data imply that a modulated immune regulation in cord blood, influenced by the 
genotype, has an impact on the development of atopic diseases later in childhood. 
At the time of manifestation of allergic and non-allergic asthma in steroid-naïve, untreated 
children at age 4-15 years, both clinical phenotypes could be distinguished by different 
pathophysiological mechanism. 
Importantly, the results of our study can help to develop specific biomarkers for differentiation 
of allergic from non-allergic asthma and may lead to a more individualized clinical treatment 
of patients with childhood asthma of allergic vs. non-allergic origin. 
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6. ZUSAMMENFASSUNG 
Das Auftreten atopischer Erkrankungen im Kindesalter hat vor allem in Industrieländern in den 
letzten Jahrzehnten drastisch zugenommen. Die zugrundeliegenden Mechanismen der 
Immunregulation im Kleinkindesalter sowie bei Manifestation der Erkrankung sind bisher 
allerdings weitgehend unbekannt. 
In meiner Doktorarbeit habe ich zu zwei unterschiedlichen Zeitpunkten (im Säuglings- und im 
Kindesalter) die Regulation verschiedener T-Zell Subpopulationen sowie den Einfluss 
genetischer Prädisposition und epigenetischer Regulation auf die Entstehung atopischer 
Erkrankungen untersucht.  
Während in zahlreichen anderen Studien atopische Erkrankungen bei Kindern und 
Erwachsenen untersucht wurden, haben wir die Immunregulation im Nabelschnurblut, und 
damit zum frühestmöglichen Zeitpunkt der Immunmaturation untersucht.  
Die zusätzliche Untersuchung der Immunantwort bei Krankheitsmanifestation im späteren 
Kindesalter (4-15 Jahre) eröffnet zudem die einzigartige Möglichkeit, wichtige 
Regulationsmechanismen in der Entstehung atopischer Erkrankungen zu identifizieren. 
 
Meine Dissertation lieferte folgende Ergebnisse: 
1) Von den in unserer Geburtskohorte untersuchten TLR Polymorphismen konnte für TLR2 
SNPs ein Einfluss auf die Expression von Treg-assoziierten Genen gezeigt werden, wobei 
die Genexpression zusätzlich vom mütterlichen Atopiestatus abhängig war. 
In der gleichen Studienpopulation konnte für IL-10 SNP Träger folgendes Muster in der T-
Zellregulation im Nabelschnurblut gezeigt werden: Neben einer erniedrigten Expression 
von Treg-assoziierten Genen konnten wir eine erniedrigte TNF-, GM-CSF (pro-
inflammatorische Zytokine) und IL-5 Sekretion (Th2 Zytokin) bei gleichzeitig erhöhtem 
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IFN-(Th1 Zytokin) zeigen. Im frühen Kindesalter (bis zu 3 Jahren) traten bei Kindern mit 
TLR und IL-10 SNPs vermehrt atopische Erkrankungen auf. 
2) Das kindliche Asthma wird in zwei Haupt-Phänotypen unterteilt, das allergische und das 
nicht-allergische Asthma. In unserer Studie konnten beide Phänotypen hinsichtlich ihrer 
zugrundeliegenden Pathophysiologie wie folgt unterschieden werden: Kinder (im Alter von 
4 bis 15 Jahren) mit allergischem Asthma wiesen, im Vergleich zu nicht-allergischen 
Asthmatikern und gesunden Kindern, eine höhere Anzahl an regulatorischen T-Zellen 
(Tregs), bei gleichzeitig verminderter suppressiver Kapazität der Tregs, auf. Eine erhöhte 
Anzahl an natürlich vorkommenden Tregs (nTregs) konnte zudem mittels epigenetischer 
Regulation der Treg-spezifischen demethylierten Region (TSDR), mit erhöhter 
Demethylierung in allergischen Asthmatikern, bestätigt werden. 
Beim Anstieg von Tregs in allergischen Asthmatikern könnte es sich um eine 
physiologische Antwort auf die allergische Entzündung handeln mit dem Ziel die 
pathologisch gesteigerte Entzündungsreaktion, zum Teil bedingt durch eine erniedrigte 
suppressive Kapazität der Tregs, zu kompensieren. Es bleibt anzumerken, dass die Kinder 
trotz oben beschriebener Regulationsmechanismen unter allergischem Asthma leiden, was 
auf eine  insgesamt unzureichende Kontrolle der pathologischen Immunreaktion hindeutet. 
Zusätzlich zeigte die Studie, dass bei Kindern mit nicht-allergischem Asthma, im Vergleich 
zu allergischen Asthmatikern und gesunden Kontrollen, sowohl das pro-inflammatorische 
Zytokin IL-1 als auch die Expression von IL-37 erhöht war. Zudem zeigten nicht-
allergische Asthmatiker einen nach Th17 verschobenen Immunphänotyp, sowie eine 
erhöhte Anzahl von Neutrophilen in peripherem Blut. 
Kinder mit nicht-allergischem Asthma unterschieden sich demnach anhand oben gezeigter 
immunologischer Mechanismen klar von Kindern mit allergischem Asthma, und zeigten 
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verglichen mit der Treg-dominierten Antwort bei allergischen Asthmatikern, eine 
gesteigerte Th17-dominierte neutrophile Entzündungsreaktion. 
Interessanterweise zeigten in unserer Studie sowohl allergische als auch nicht-allergische 
Asthmatiker einen Th2-dominierten Phänotyp. 
3) Mithilfe von Microarray-Expressionsanalyse und nachfolgender Validierung der 
Genexpression mittels qRT-PCR, konnten wir neue spezifische Genexpressionsprofile für 
allergische und nicht-allergische Asthmatiker identifizieren. Dabei war die Expression der 
beiden Calcium-bindenden Proteine CD93 und S100A9 und von TREM1, welches mit 
neutrophiler Entzündung assoziiert ist, in nicht-allergischen Asthmatikern im Vergleich zu  
allergischen Asthmatikern und gesunden Kontrollen signifikant erhöht. Zusätzlich konnten 
wir zeigen, dass sich die beiden Asthma-Phänotypen hinsichtlich ihrer Expression von 
Genen aus der TLR-, Calcium- sowie der mTOR-Signalkaskade unterscheiden. 
 
Zusammenfassend zeigen unsere Daten, dass bereits zum Zeitpunkt der Geburt eine veränderte 
Immunregulation, beeinflusst durch den Genotyp, eine Auswirkung auf die Prävalenz 
atopischer Erkrankungen im Kindesalter hat. 
Bei Erstmanifestation von allergischem und nicht-allergischem Asthma in steroid-naiven, 
vorher unbehandelten Kindern im Alter von 4 bis 15 Jahren, konnten die beiden Phänotypen 
durch verschiedene pathophysiologische Mechanismen unterschieden werden. 
Zusammenfassend können unsere Studienergebnisse bei der Entwicklung spezifischer 
Biomarker zur besseren Differenzierung und gezielteren Therapie von allergischem versus 
nicht-allergischem Asthma beitragen. 
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10. ABBREVIATIONS 
 
AA   Allergic asthmatic(s) 
AD   Atopic dermatitis 
AHR   Airway hyperresponsiveness 
BHR   Bronchial hyperresponsiveness 
bp   Basepair 
BAL   Bronchoalveolar lavage  
BSA    Bovine serum albumin  
CBMC  Cord blood mononuclear cell 
CD   Cluster designation  
cDNA   Coding DNA 
CLARA  Clinical Asthma Research Association 
CT   Cycle threshold 
CTLA-4   Cytotoxic T-Lymphocyte antigen 4 
Derp1   Dermatophagoides pteronyssinus; house dust mite 
DNA   Deoxyribonucleic acid 
FACS   Fluorescence activated cell sorting  
FBS   Fetal bovine serum 
FOXP3  Forkhead box P3 
fwd   Forward 
GITR   Glucocorticoid-induced TNF receptor 
GMC-SF  Granulocyte-macrophage colony-stimulating factor 
GWAS  Genome-wide association study 
HC   Healthy control(s) 
HWE   Hardy-Weinberg equilibrium 
IFN-   Interferon-gamma 
IgE    Immunglobulin E 
IL   Interleukin 
IQR   Interquartile range 
LAG3    Lymphocyte activation gene-3 
LD   Linkage disequilibrium 
LpA   Lipid A 
M   Media, unstimulated 
MAF   Minor allele frequency 
MALDI-TOF MS Matrix assisted laser desorption-time of flight mass spectrometry 
mRNA  Messenger RNA  
NA   Non-allergic asthmatic(s) 
OR   Odds ratio 
p   p-value 
PI   PMA/Ionomycin 
PAULCHEN  Prospective Cord Blood Study in Rural Southern Germany 
PAULINA Paediatric Alliance for Unselected Longitudinal Investigation of 
Neonates for Allergies 
PBMC   Peripheral blood monocytes 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PHA   Phytohaemagglutinin 
PMA   Phorbol 12-myristate 13-acetate 
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Ppg   Peptidoglycan 
Real-time RT-PCR Real-time reverse-transcriptase-PCR 
rev   Reverse 
RA   Retinoic acid 
RAST   Radioallergosorbent test 
RNA   Ribonucleic acid 
RORC   Retinoic acid receptor-related orphan receptor C 
rs   Reference SNP 
S100A9  S100 calcium binding protein A9 
SD   Standard deviation 
SNP   Single nucleotide polymorphism 
TCR   T cell receptor 
Th cells  T helper cell 
TLR   Toll-like receptor 
TNF   Tumor necrosis factor-alpha 
Treg   Regulatory T cell 
TREM1  Triggering receptor expressed on myeloid cells 1 
TSDR    Treg-specific demethylated region 
t-test   Statistical test: Student’s t distribution  
UTR   Untranslated region 
WT   Wildtype allele 
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